

# GLOBAL JOURNAL

OF MEDICAL RESEARCH: K

## Interdisciplinary

An Observational Analysis

Comparing Health Indicators

### Highlights

Quality of Life Comparison

Data and Edits in Healthcare

Discovering Thoughts, Inventing Future

VOLUME 15


ISSUE 2

VERSION 1.0



GLOBAL JOURNAL OF MEDICAL RESEARCH: K  
INTERDISCIPLINARY

---



GLOBAL JOURNAL OF MEDICAL RESEARCH: K  
INTERDISCIPLINARY

---

VOLUME 15 ISSUE 2 (VER. 1.0)

OPEN ASSOCIATION OF RESEARCH SOCIETY

© Global Journal of Medical Research . 2015.

All rights reserved.

This is a special issue published in version 1.0 of "Global Journal of Medical Research." By Global Journals Inc.

All articles are open access articles distributed under "Global Journal of Medical Research"

Reading License, which permits restricted use. Entire contents are copyright by of "Global Journal of Medical Research" unless otherwise noted on specific articles.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without written permission.

The opinions and statements made in this book are those of the authors concerned. Ultraculture has not verified and neither confirms nor denies any of the foregoing and no warranty or fitness is implied.

Engage with the contents herein at your own risk.

The use of this journal, and the terms and conditions for our providing information, is governed by our Disclaimer, Terms and Conditions and Privacy Policy given on our website <http://globaljournals.us/terms-and-condition/menu-id-1463/>

By referring / using / reading / any type of association / referencing this journal, this signifies and you acknowledge that you have read them and that you accept and will be bound by the terms thereof.

All information, journals, this journal, activities undertaken, materials, services and our website, terms and conditions, privacy policy, and this journal is subject to change anytime without any prior notice.

Incorporation No.: 0423089  
License No.: 42125/022010/1186  
Registration No.: 430374  
Import-Export Code: 1109007027  
Employer Identification Number (EIN):  
USA Tax ID: 98-0673427

## Global Journals Inc.

(A Delaware USA Incorporation with "Good Standing"; **Reg. Number: 0423089**)

Sponsors: *Open Association of Research Society*  
*Open Scientific Standards*

### *Publisher's Headquarters office*

Global Journals Headquarters  
301st Edgewater Place Suite, 100 Edgewater Dr.-Pl,  
Wakefield MASSACHUSETTS, Pin: 01880,  
United States of America  
USA Toll Free: +001-888-839-7392  
USA Toll Free Fax: +001-888-839-7392

### *Offset Typesetting*

Global Journals Incorporated  
2nd, Lansdowne, Lansdowne Rd., Croydon-Surrey,  
Pin: CR9 2ER, United Kingdom

### *Packaging & Continental Dispatching*

Global Journals  
E-3130 Sudama Nagar, Near Gopur Square,  
Indore, M.P., Pin:452009, India

### *Find a correspondence nodal officer near you*

To find nodal officer of your country, please  
email us at [local@globaljournals.org](mailto:local@globaljournals.org)

### *eContacts*

Press Inquiries: [press@globaljournals.org](mailto:press@globaljournals.org)  
Investor Inquiries: [investors@globaljournals.org](mailto:investors@globaljournals.org)  
Technical Support: [technology@globaljournals.org](mailto:technology@globaljournals.org)  
Media & Releases: [media@globaljournals.org](mailto:media@globaljournals.org)

### *Pricing (Including by Air Parcel Charges):*

#### *For Authors:*

22 USD (B/W) & 50 USD (Color)  
Yearly Subscription (Personal & Institutional):  
200 USD (B/W) & 250 USD (Color)



INTEGRATED EDITORIAL BOARD  
(COMPUTER SCIENCE, ENGINEERING, MEDICAL, MANAGEMENT, NATURAL  
SCIENCE, SOCIAL SCIENCE)

---

**John A. Hamilton, "Drew" Jr.,**  
Ph.D., Professor, Management  
Computer Science and Software  
Engineering  
Director, Information Assurance  
Laboratory  
Auburn University

**Dr. Henry Hexmoor**  
IEEE senior member since 2004  
Ph.D. Computer Science, University at  
Buffalo  
Department of Computer Science  
Southern Illinois University at Carbondale

**Dr. Osman Balci, Professor**  
Department of Computer Science  
Virginia Tech, Virginia University  
Ph.D. and M.S. Syracuse University,  
Syracuse, New York  
M.S. and B.S. Bogazici University,  
Istanbul, Turkey

**Yogita Bajpai**  
M.Sc. (Computer Science), FICCT  
U.S.A. Email:  
yogita@computerresearch.org

**Dr. T. David A. Forbes**  
Associate Professor and Range  
Nutritionist  
Ph.D. Edinburgh University - Animal  
Nutrition  
M.S. Aberdeen University - Animal  
Nutrition  
B.A. University of Dublin- Zoology

**Dr. Wenying Feng**  
Professor, Department of Computing &  
Information Systems  
Department of Mathematics  
Trent University, Peterborough,  
ON Canada K9J 7B8

**Dr. Thomas Wischgoll**  
Computer Science and Engineering,  
Wright State University, Dayton, Ohio  
B.S., M.S., Ph.D.  
(University of Kaiserslautern)

**Dr. Abdurrahman Arslanyilmaz**  
Computer Science & Information Systems  
Department  
Youngstown State University  
Ph.D., Texas A&M University  
University of Missouri, Columbia  
Gazi University, Turkey

**Dr. Xiaohong He**  
Professor of International Business  
University of Quinipiac  
BS, Jilin Institute of Technology; MA, MS,  
PhD, (University of Texas-Dallas)

**Burcin Becerik-Gerber**  
University of Southern California  
Ph.D. in Civil Engineering  
DDes from Harvard University  
M.S. from University of California, Berkeley  
& Istanbul University

**Dr. Bart Lambrecht**

Director of Research in Accounting and Finance  
Professor of Finance  
Lancaster University Management School  
BA (Antwerp); MPhil, MA, PhD  
(Cambridge)

**Dr. Carlos García Pont**

Associate Professor of Marketing  
IESE Business School, University of Navarra  
Doctor of Philosophy (Management),  
Massachusetts Institute of Technology (MIT)  
Master in Business Administration, IESE,  
University of Navarra  
Degree in Industrial Engineering,  
Universitat Politècnica de Catalunya

**Dr. Fotini Labropulu**

Mathematics - Luther College  
University of Regina  
Ph.D., M.Sc. in Mathematics  
B.A. (Honors) in Mathematics  
University of Windsor

**Dr. Lynn Lim**

Reader in Business and Marketing  
Roehampton University, London  
BCom, PGDip, MBA (Distinction), PhD,  
FHEA

**Dr. Mihaly Mezei**

ASSOCIATE PROFESSOR  
Department of Structural and Chemical  
Biology, Mount Sinai School of Medical  
Center  
Ph.D., Eötvös Loránd University  
Postdoctoral Training,  
New York University

**Dr. Söhnke M. Bartram**

Department of Accounting and Finance  
Lancaster University Management School  
Ph.D. (WHU Koblenz)  
MBA/BBA (University of Saarbrücken)

**Dr. Miguel Angel Ariño**

Professor of Decision Sciences  
IESE Business School  
Barcelona, Spain (Universidad de Navarra)  
CEIBS (China Europe International Business School).  
Beijing, Shanghai and Shenzhen  
Ph.D. in Mathematics  
University of Barcelona  
BA in Mathematics (Licenciatura)  
University of Barcelona

**Philip G. Moscoso**

Technology and Operations Management  
IESE Business School, University of Navarra  
Ph.D in Industrial Engineering and  
Management, ETH Zurich  
M.Sc. in Chemical Engineering, ETH Zurich

**Dr. Sanjay Dixit, M.D.**

Director, EP Laboratories, Philadelphia VA  
Medical Center  
Cardiovascular Medicine - Cardiac  
Arrhythmia  
Univ of Penn School of Medicine

**Dr. Han-Xiang Deng**

MD., Ph.D  
Associate Professor and Research  
Department Division of Neuromuscular  
Medicine  
Davee Department of Neurology and Clinical  
Neuroscience  
Northwestern University  
Feinberg School of Medicine

**Dr. Pina C. Sanelli**

Associate Professor of Public Health  
Weill Cornell Medical College  
Associate Attending Radiologist  
NewYork-Presbyterian Hospital  
MRI, MRA, CT, and CTA  
Neuroradiology and Diagnostic  
Radiology  
M.D., State University of New York at  
Buffalo, School of Medicine and  
Biomedical Sciences

**Dr. Roberto Sanchez**

Associate Professor  
Department of Structural and Chemical  
Biology  
Mount Sinai School of Medicine  
Ph.D., The Rockefeller University

**Dr. Wen-Yih Sun**

Professor of Earth and Atmospheric  
SciencesPurdue University Director  
National Center for Typhoon and  
Flooding Research, Taiwan  
University Chair Professor  
Department of Atmospheric Sciences,  
National Central University, Chung-Li,  
TaiwanUniversity Chair Professor  
Institute of Environmental Engineering,  
National Chiao Tung University, Hsin-  
chu, Taiwan.Ph.D., MS The University of  
Chicago, Geophysical Sciences  
BS National Taiwan University,  
Atmospheric Sciences  
Associate Professor of Radiology

**Dr. Michael R. Rudnick**

M.D., FACP  
Associate Professor of Medicine  
Chief, Renal Electrolyte and  
Hypertension Division (PMC)  
Penn Medicine, University of  
Pennsylvania  
Presbyterian Medical Center,  
Philadelphia  
Nephrology and Internal Medicine  
Certified by the American Board of  
Internal Medicine

**Dr. Bassey Benjamin Esu**

B.Sc. Marketing; MBA Marketing; Ph.D  
Marketing  
Lecturer, Department of Marketing,  
University of Calabar  
Tourism Consultant, Cross River State  
Tourism Development Department  
Co-ordinator , Sustainable Tourism  
Initiative, Calabar, Nigeria

**Dr. Aziz M. Barbar, Ph.D.**

IEEE Senior Member  
Chairperson, Department of Computer  
Science  
AUST - American University of Science &  
Technology  
Alfred Naccash Avenue – Ashrafieh

## PRESIDENT EDITOR (HON.)

---

### **Dr. George Perry, (Neuroscientist)**

Dean and Professor, College of Sciences

Denham Harman Research Award (American Aging Association)

ISI Highly Cited Researcher, Iberoamerican Molecular Biology Organization

AAAS Fellow, Correspondent Member of Spanish Royal Academy of Sciences

University of Texas at San Antonio

Postdoctoral Fellow (Department of Cell Biology)

Baylor College of Medicine

Houston, Texas, United States

## CHIEF AUTHOR (HON.)

---

### **Dr. R.K. Dixit**

M.Sc., Ph.D., FICCT

Chief Author, India

Email: [authorind@computerresearch.org](mailto:authorind@computerresearch.org)

## DEAN & EDITOR-IN-CHIEF (HON.)

---

### **Vivek Dubey(HON.)**

MS (Industrial Engineering),

MS (Mechanical Engineering)

University of Wisconsin, FICCT

Editor-in-Chief, USA

[editorusa@computerresearch.org](mailto:editorusa@computerresearch.org)

### **Sangita Dixit**

M.Sc., FICCT

Dean & Chancellor (Asia Pacific)

[deanind@computerresearch.org](mailto:deanind@computerresearch.org)

### **Suyash Dixit**

(B.E., Computer Science Engineering), FICCTT

President, Web Administration and

Development , CEO at IOSRD

COO at GAOR & OSS

### **Er. Suyog Dixit**

(M. Tech), BE (HONS. in CSE), FICCT

SAP Certified Consultant

CEO at IOSRD, GAOR & OSS

Technical Dean, Global Journals Inc. (US)

Website: [www.suyogdixit.com](http://www.suyogdixit.com)

Email: [suyog@suyogdixit.com](mailto:suyog@suyogdixit.com)

### **Pritesh Rajvaidya**

(MS) Computer Science Department

California State University

BE (Computer Science), FICCT

Technical Dean, USA

Email: [pritesht@computerresearch.org](mailto:pritesht@computerresearch.org)

### **Luis Galárraga**

J!Research Project Leader

Saarbrücken, Germany



## CONTENTS OF THE ISSUE

---

- i. Copyright Notice
  - ii. Editorial Board Members
  - iii. Chief Author and Dean
  - iv. Contents of the Issue
- 
1. The Flat Panel Volumetric Computed Tomography in in Vivo Tissue Engineering of Bone: Possibilities and Limitations. *1-8*
  2. Chocolate with High Cocoa Content as a Weight-Loss Accelerator. *9-14*
  3. Quality of Life Comparison in Chronic Pancreatitis Patients: A Case-Control Study. *15-19*
  4. Comparing Health Indicators: Colombia and the OECD. *21-27*
  5. Intranasal Antifungal Therapy in Patients with Chronic Illness Associated with Mold and Mycotoxins: An Observational Analysis. *29-33*
  6. Data and Edits in Healthcare Information Management. *35-39*
- 
- v. Fellows and Auxiliary Memberships
  - vi. Process of Submission of Research Paper
  - vii. Preferred Author Guidelines
  - viii. Index



GLOBAL JOURNAL OF MEDICAL RESEARCH: K  
INTERDISCIPLINARY

Volume 15 Issue 2 Version 1.0 Year 2015

Type: Double Blind Peer Reviewed International Research Journal

Publisher: Global Journals Inc. (USA)

Online ISSN: 2249-4618 & Print ISSN: 0975-5888

# The Flat Panel Volumetric Computed Tomography in In Vivo Tissue Engineering of Bone: Possibilities and Limitations

By Christian Beltzer & Stefan Endres

*University Orthopedic Surgery Rheinfelden / Baden, Germany*

**Abstract-** The scaffold-based tissue engineering of bones is an extremely promising concept with regard to the regeneration of major bone defects due to trauma, tumour or developmental abnormalities as well as for the treatment of pseudo-arthroses. The in vivo testing of implants is a significant phase in the development of specimens for the clinical application of suitable scaffolds. The collection of an optimal amount of information from these initial – clinical - tests demands, ideally, the most diagnostically conclusive studies possible. We tested the procedure of flat panel volumetric computer tomography (fpvCT) thus far virtually untried in the area of bone tissue engineering for the in vivo evaluation of small animal experiments and compared it with other methods (projection radiography, micro-CT, histology).

**GJMR-K Classification:** *NLMC Code: WG 141.5.T6*



THE FLAT PANEL VOLUMETRIC COMPUTED TOMOGRAPHY IN IN VIVO TISSUE ENGINEERING OF BONE POSSIBILITIES AND LIMITATIONS

*Strictly as per the compliance and regulations of:*



# The Flat Panel Volumetric Computed Tomography in in Vivo Tissue Engineering of Bone: Possibilities and Limitations

Christian Beltzer <sup>α</sup> & Stefan Endres <sup>σ</sup>

**Abstract-** The scaffold-based tissue engineering of bones is an extremely promising concept with regard to the regeneration of major bone defects due to trauma, tumour or developmental abnormalities as well as for the treatment of pseudo-arthroses. The in vivo testing of implants is a significant phase in the development of specimens for the clinical application of suitable scaffolds. The collection of an optimal amount of information from these initial – clinical – tests demands, ideally, the most diagnostically conclusive studies possible. We tested the procedure of flat panel volumetric computer tomography (fpvCT) thus far virtually untried in the area of bone tissue engineering for the in vivo evaluation of small animal experiments and compared it with other methods (projection radiography, micro-CT, histology). The main questions were whether in situ osteosynthesis decreased representability (artefact formation), the scaffold could be demonstrated by means of fpvCT, and whether the course of degradation and bone growth could be observed, the course of growth precisely evaluated, neoformation of vessels demonstrated in the osteotomic cleft, and what conclusions could be reached with regard to animal models and osteosynthesis.

We worked with a CT from the company GE Global Research, Niskayuna, New York. This flat panel volumetric computed tomograph functions with two flat panel radiographic sensors with a resolution of 1024x1024 pixels in each instance.

We were able to demonstrate that the fpvCT is an alternative to be considered seriously in terms of the in vivo evaluation of small animal experiments on behalf of scaffold-based tissue engineering. It is superior to projection radiography and can replace the micro-CT, if high resolution is not required. Major advantages of this method over the micro-CT are the shorter scan time, the lower radiation exposure, the larger presentable area and the possibility of carrying out several experiments on a single animal over the course of time. In terms of resolution the fpvCT is superior to the micro-CT. Above all with respect to issues concerning the neoformation of bone and the differentiation between degraded scaffold and new bone, histology is indispensable.

*Author α : Bundeswehrkrankenhaus Ulm, Viszeral- und Thoraxchirurgie BwK Ulm, Baden-Württemberg.*

*Author σ : Klinik für orthopädische Chirurgie, Endoprothesenzentrum Rheinfelden / Baden, Baden-Württemberg.*

*e-mail: endres.stefan@klinloe.de*

## I. INTRODUCTION

In the scaffold-based tissue engineering of bones, experiments on small animals are the first practical test of the scaffold and a significant intermediate step on the road to the clinical testing of the material. As an experimental model the critical size defect (CSD, defect of critical dimensions) has proven its value [1,2]. Frequently utilised on the Ossa longa of animals, stabilisation of a defect requires sufficient osteosynthesis. Babis et al were able to demonstrate that stable osteosynthesis is a decisive condition for the mending of the scaffold [3]. This makes osteosynthesis a critical factor in the breadboard. Additionally, the correct location of the scaffold, the course of degradation and that of bone mending within the defect must be presented as accurately as possible and, ideally, in terms of their course.

Therefore, central issues with regard to the model of the critical size defect in scaffold-based tissue engineering of bone are the following:

- Is the scaffold situated correctly postoperatively (in the osteotomic cleft)?
- What is the degradation behaviour of the scaffold over time?
- Is there bone ingrowth into the scaffold?
- Is osteogenesis occurring in the scaffold?
- What characteristics demonstrate the osteogenic activity?
- How do various scaffolds perform in comparative terms?
- Is the defect closing?

Therefore, suitable assessment methods are required for monitoring the course and outcome of the series of experiments, evaluating them and answering all relevant of the above questions. Significant here is above all the monitoring of the mending process in vivo, including in order to be able to recognise and evaluate the influence of the breadboard, above all that of osteosynthesis, upon the results.

## II. STATUS QUO

Presently, it is above all projection radiography, the micro-CT and histology that are used for the evaluation of in vivo experiments regarding scaffold-based tissue engineering. Unfortunately, with these methods either resolution and/or three-dimensional presentability are insufficient and/or the method is not compatible with the survival of the animal and an intact specimen.

Based on the high radiation dosage and the long exposure time, the micro-CT is not indicated for repeated tests on an individual in vivo, while additionally usually the volume to be studied must be significantly reduced [4]. Added to this is the fact that osteosynthetic material frequently causes very significant artefacts, so that this must usually be removed first. This at least partially destroys the specimen.

The same applies to histology: the bone scaffold structure must be cut. This results in a loss of part of the specimen. Additionally, the preparatory process is protracted and complex, and three-dimensional presentation is not possible.

Projection radiography as a two-dimensional system can be repeated frequently over the course of time. Nonetheless, the bone mending process can only be assessed to a limited extent due to the lack of three-dimensionality and this indeed can lead to erroneous assessments with regard to dual-plane exposures. In order to at least partially compensate for these disadvantages, some research groups such as Fialkov et al have chosen to use scores that they themselves have developed to assess roentgen images [5].

Conventional computer tomography permits three-dimensional representation, however with a maximal resolution of 0.5 x 0.5mm in the plane and 0.25-1mm in the z-axis. This is too low for the detailed representation of such bony structures as trabeculae and the scaffold [6].

Thus it is clear that a sparing procedure for the high-resolution, three-dimensional representation of the mending process in vivo over the course of time is still to be striven for.

Flat panel volumetric computed tomography provides a high-resolution, three-dimensional representation of tissue in vivo. Obert et al were able to visualise bones down to their trabecular structure in mice [4]. It is also possible to demonstrate vascular neoformation using contrast media [7,8]. This is a critical point in the tissue engineering of bones, because vascular neoformation or the ingrowth of vessels in the scaffold is a basic requirement for the formation of new bone in a defect.


Weinand et al utilised the fpvCT to measure a distal thumb phalanx in humans in order to use CAD technology with these data to produce a scaffold. After cell colonisation and implantation of the scaffold

subcutaneously in a mouse, the fpvCT was used to monitor the course of the procedure [9].

Thus far the fpvCT has not yet been used to evaluate an in vivo model on a small animal based on critical size defect. Our objective was to determine whether this promising method represents an alternative to the already known methods for evaluating scaffold-based tissue engineering.

## III. MATERIAL AND METHODS

The rabbit was obtained from the company Behring Aventis Marburg and allowed to become accustomed to its stables for a week before the operation. Premedication was effected with atropine, and anaesthesia induced with xylazine and ketamine IM. The left femur was shaved and disinfected, the operative field sterilely draped and disinfected again. In summary, a 12 mm piece was removed from the femoral diaphysis and a scaffold of calcium phosphate/PLGA was placed. Osteosynthetic supply was effected using a mandibular plate (Stryker) and 2.7 mm blocking screws. The screw length was chosen individually (10-16 mm). Caprofen was used for postoperative pain therapy.



*Figure 1 :* Operation site; recognisable are the scaffold introduced into the osteotomy, and osteosynthesis

The first fpvCT evaluation took place two weeks, and the second four weeks, postoperatively. Thereafter an fpvCT was carried out every four weeks. After 20 weeks the rabbit was killed, the osteosynthetic material was removed and a micro-CT and a histological examination of the osteotomic cleft took place. Parallel projection radiographic studies were carried out.

The same anaesthetic method was chosen for the fpvCT as described above. First a native and then a contrast CT were carried out. The studies were carried out using a new type of CT from the company GE Global Research, Niskayuna, New York. This flat panel volumetric computed tomograph comprises two flat

panel roentgen sensors with a resolution of 1024 x 1024 pixels in each instance. The maximal Z-axis is 21cm per scan. A more precise description of the volume computer tomograph is contained in the literature [4,7,8]. Our images were obtained with 120 kV and 40 mA. The rotation time of a step was 8 seconds at a length on the Z-axis of 42 mm. Two steps were recorded, resulting in a Z-axis of 84 mm.

For the application of the contrast medium, after induction of anaesthesia a Braun cannula was introduced into the aural vein of the rabbit. 10 ml of contrast medium (Imeron 300, Altana, Constance) was injected 50 seconds before the scan. At an average number of exposures of 420, a voxel magnitude of 0.2 mm<sup>3</sup> and a field of view of 102x102x84 mm<sup>3</sup> were yielded in the reconstruction.

After four and 20 weeks, in each instance half the rabbits were killed. The left femur was removed, embedded in rigid plastic (Technovit, Fa. Kulzer) and the osteosynthetic material was removed. Then the micro-CT was carried out. The histological specimen was prepared after the micro-CT using the thin slice technique, and then dyed with toluidine blue.

The examination and evaluation of the fpvCT data was undertaken without knowledge of the results of the micro-CT and histology. The fpvCT data were reconstructed using a Linux-based network of seven 7 dual core 2.2GHz processor PCs and a cone beam-filtered back projection algorithm. The reconstruction time was approximately 13 minutes. The images were displayed on an Advantage Workstation, Version 4.1 from the company GE Medical Systems, based on a Linux PC with dual core 2.2GHz processor and 4GB RAM. The evaluation was effected in maximum intensity projection (MIP) and volume rendering representation, viewing both the three-dimensional reconstruction and the sagittal, axial and coronary interfaces.

After evaluation of the fpvCT, the results were compared to those of the micro-CT and the histology.

#### IV. RESULTS

A total of 19 animals were observed over the defined experimental period. Of these, 8 animals had implanted scaffolds and one animal had an empty defect for 4 weeks and 8 animals with scaffolds and two animals with empty defects over 20 weeks.

Four animals were excluded for reasons of osteosynthetic insufficiency, and four animals experienced complications during the application of the contrast medium (see below).

##### a) Projection radiography

During postoperative roentgen controls, no scaffold could be demonstrated in the osteotomic cleft. An irregular shadowing was noted in some animals; however this could not be identified unequivocally, nor was it possible to determine precise contours.


Consequently, the correct positioning of the scaffold and the degradation could not be demonstrated or confirmed.

Bone formation in the osteotomic cleft was demonstrated in all animals. Nonetheless, it was impossible to differentiate with certainty between ingrowing bone and bone neoformation in the scaffold. Based on the growth sample one could only make conjectures. During the further course, in the presence of a virtually closed osteotomic cleft, no further differentiation was possible.

After 20 weeks, in the context of an empty defect the closure of the osteotomic cleft was suspected, because a continuous cortical line could be demonstrated on both planes (see Fig 2).



**Figure 2 :** In native radiographic terms, the fracture cleft appears closed (upper picture lateral projection, lower picture ap-projection, sinistral distal, dexter proximal)



Osteosynthesis could be assessed well on x-rays. For example, the four osteosynthetic insufficiencies in the visualisation on two planes were observed immediately. For the most part there was avulsion of the screws distal to the osteotomic cleft.


#### b) Flat panel volumetric computer tomography

The data sets were evaluated at the workstation in maximum intensity projection. First the three-dimensionally reconstructed femur was viewed, and

then the interfaces parallel, perpendicular and axial to the lamina. Based on the isotropic voxels it was possible to set any other desired interface without any compromise in image quality.

In addition to the bone corticalis, trabecular structures were also shown quite well. In the sectional images one could even identify extremely fine fissures in the bone and changes in the bone structure (see Fig 3).

**Figure 3 :** Trabeculae, scaffold and osteosynthesis can be clearly recognised with the fpvCT without significant artefact formation (axial slices, left picture through the diaphysis of the femur proximal the osteotomic cleft, central picture through the femoral neck, right picture through the middle of the osteotomic cleft)




All in all, there was only very minimal artefact formation due to the osteosynthetic material. Shadowing was seen parallel to the osteosynthetic material and ray-like artefacts radiated from the lamina (see Fig 3). These, however, did not significantly hinder the evaluation.

Postoperatively one could identify the scaffold very well, and delineate it from the surrounding bone and connective tissue, in all the animals (see Fig 3 and 4). It was always positioned correctly in the osteotomic

cleft. The degradation behaviour, as well, could also be observed very well up to 12-16 months postoperatively. At these times the scaffold was degraded to such an extent that it could no longer be shown sufficiently via fpvCT, nor could it any longer be differentiated from bone.




**Figure 4 :** The scaffold is clearly recognisable in the osteotomic cleft (left picture coronar slice in the middle of the osteotomic cleft, right picture sagital slice in the middle of the osteotomic cleft)



The bone growing in from the outside could be clearly delineated from the bone formed in the osteotomic cleft on the fpvCT. Various different growth forms of the ingrowing bone could also be identified, thus yielding significant information concerning the

breadboard. For example, cap formation beyond the medullary space radiating from the corticalis was demonstrated in nearly all the test animals, which enclosed the medullary space and thus made mending of the scaffold impossible (see Fig 5).

**Figure 5 :** Growth behaviour of the bone over the course of time (indicated in weeks from top to bottom, right column the reconstructed radiographs, left column coronar slices in the middle of the osteotomic cleft, sinistral distal, dexter proximal)




For example, on the fpvCT no bony connection between ingrowing bone and scaffold could be demonstrated; gaps always remained. During the closure of the osteotomic cleft suspected on projection

roentgen, as well, it was possible on fpvCT to demonstrate a non-union (see Fig 6). Sclerotic zones were demonstrated in the scaffold over the course of time, but one could not differentiate, over the course of

time, between bone neoformation and compressed calcium phosphate components of the scaffold.


*Figure 6 :* Identifiable non-union of the bone that appeared bridged on projection roentgen



The pfvCT was extraordinarily useful for the assessment of the osteosynthetic process. By way of the high-resolution representation of the entire femur, for the first time fine fissures in the bone between the screws could be identified. For example, one could

derive significant information concerning the formation of screw fissures and thus osteosynthetic failure. Stress-related remodelling around the screws in the bone could also be clearly identified (see Fig 7).

*Figure : 7* Osteosynthetic failure after intraoperative fissure formation (coronar slices in the first two rows, on the left directly below the plate, on the right the opposite cortices), lowest sagittal slice showing the dislocation of the plate and screws (distal sinistral, proximal dexter)



To represent the vessels in the region of the femoral bone and the osteotomic cleft, a contrast medium CT was carried out on the test animals. It was expected that newly proliferating vessels would be identified. However, no blood vessels could be identified in the area of the bone and the osteotomic cleft. Vessels were only visualised in the large leg veins. In 4 test animals a fatal circulatory reaction occurred shortly after application of the contrast medium. However, this never occurred at the first administration, but only at the third

or fourth test. We suspect stress- and volume-related acute circulatory insufficiency. In the absence of usefulness and considering the high risk for the animals, the contrast CT was then terminated.

## V. DISCUSSION

The fpvCt is a relatively new procedure for the high resolution, three-dimensional representation of tissue in vivo. It has been demonstrated in various publications that it is excellent for the representation of

bone details and vessels and is superior to traditional computer tomography [4, 6, 8-11]. At comparable radiation dosage and test duration, the fpvCT achieves significantly better local resolution (in our case 0.2mm3) than traditional computer tomography. By means of the technique of isotopes, that is to say cubic voxels, any chosen interface can be represented without compromise in quality. This is extremely useful above all in the precise assessment of bone growth. In comparison with the micro-CT, the advantage of the fpvCT is that it requires a much lower dosage of radiation, so that it can be used several times in one animal in vivo. The scan time is also significantly shorter (here 16 seconds).

Another decisive point is that studies of osteosynthesis were possible without significant artefact formation by the osteosynthetic material. This had not yet been demonstrated in the past. Additionally, the entire femur could be represented, something which had otherwise only been possible by way of projection radiography. For example, the entire osteosynthetic process could be observed in detail throughout the test period. This image material allowed significant conclusions to be reached with respect to the methodology of the critical size defect and, above all, osteosynthesis. For the first time, as well, the scaffold could be represented in vivo, allowing it to be demonstrated that the implant was in the correct location postoperatively and that the implant did not contract rapidly. Additionally, the degradation of the scaffold could be observed and the implant could be represented for a considerably longer time than is the case with projection roentgen. For a differentiation between bone neoformation on the one hand and the calcium phosphatase phase of the scaffold on the other, the resolution did not suffice, that is to say that no bone neoformation could be demonstrated in the scaffold. Based on the sclerotic zones in the scaffold, however, the suspicion is great.

Prior to the fpvCT studies, there had been considerable hope that vessels would be visualised. After the successful visualisation of neoangiogenesis in tumours in the mouse [7, 8] we hoped to be able to show vascular neoformation in and around the osteotomic cleft in vivo by way of contrast media using the fpvCT. However, this did not occur. Indeed it was possible to show the larger femoral vessels, however no small vessels in and around the bones or indeed in the osteotomic cleft could be represented. This was probably attributable to the field of view that was too large in comparison with the very small vessels. On the other hand, however, no central necrosis could be demonstrated. This was a clear indication of newly occurring, intact vessel supply in the osteotomic cleft.

Another critical point was the death of four rabbits in the context of the application of the contrast medium. An allergic reaction was most improbable,

because the deaths occurred at the earliest at the time of the fourth contrast medium application. We assume that the rabbits, already under considerable stress due to their transport and examination (induction of anaesthesia), suffered circulatory shock when the contrast medium was administered. Rabbits are animals that are quite sensitive to stress, making a change in location and an unfamiliar environment particularly dangerous for them. According to our experience, an accustomisation phase of one to two hours in a quiet and air conditioned room prior to the study significantly lowers the stress load and therefore the cardiorespiratory risk.

In addition to the great advantages with respect to the representation of bones, a disadvantage is certainly the rarity of the fpvCT. Because the method is still only rarely used, one must generally expect long travel times or, better yet, the entire test process could take place where the fpvCTs are located, in order to spare the animals long transport periods. Another disadvantage in comparison with projection radiography is the significantly greater cost per procedure, while on the other hand the process does afford considerably more accurate statements concerning the course of mending. However, the fpvCT is not sufficient as a sole evaluation method, because even though the scaffold can indeed be shown, no concrete statements can be made concerning bone and vascular neoformation in the scaffold and osteotomic cleft. Unfortunately, a program for the quantification of bone ingrowth in the osteotomic cleft does not exist yet, something which could facilitate objectivisation of the results. At the moment there is only qualitative analysis. This is, however, a very valuable instrument for observing processes in the bone and osteotomic cleft over the course of time, promising to yield significant information concerning the breadboard and methodology.

## VI. CONCLUSION

The fpvCT is more than simply an alternative to the projection roentgen and micro-CT. Under certain conditions, it can replace both of those evaluation methods. For example, qualitatively it is superior to the projection x-ray in every aspect, with its only disadvantage being higher costs and more test-related expenditures. The micro-CT can also be replaced if higher resolution can be done without. Beyond that, in our opinion the micro-CT offers no advantages over the fpvCT. The representation of very small vessels can be achieved by a smaller field of view, which would then require further examination and the administration of contrast medium. More extensive knowledge could only be realised through histology, which in terms of certain issues cannot be replaced by the fpvCT.

## REFERENCES RÉFÉRENCES REFERENCIAS

1. Jeffrey O Hollinger and James C Kleinschmidt, The Critical Size Defect as an Experimental Model To Test Bone Repair Materials, *J Craniofac Surg.* 1990;1:60-68.
2. L LeGuehennec L, Goyenvallée E, Aguado E, Hochmand-Cuny M, Enkel B, Pilet P, Daculsi G and Layrolle P. Small-animal models for testing macroporous ceramic bone substitutes. *J Biomed Mater Res B Appl Biomater.* 2005;72:69-78.
3. Babis CG, Soucacos PN. Bone Scaffolds: The Role of Mechanical Stability and Instrumentation. *Injury.* 2005;Suppl 4:S34-44.
4. Obert M, Ahlemeyer B, Baumgart-Vogt E, Traupe H. Flat-Panel Volumetric Computed Tomography A New Method for Visualizing Fine Bone Detail in Living Mice. *J Comp Assist Tomograph.* 2005;4: 560-565.
5. Fialkov JA, Holy CE, Shoichet MS, Davies JE. In vivo bone engineering in a rabbit femur. *J Craniofac Surg.* 2003;3:324-332.
6. Schaaf H, Streckbein P, Obert M, Goertz B, Christophis P, Howaldt HP, Traupe H. High resolution imaging of craniofacial bone specimens by flat-panel volumetric computed tomography. *J Cranio-Maxillofac Surg.* 2008;4:234-238.
7. Kiessling F, Greschus S, Lichy MP, Block M Fink C, Vosseleer S, Moll J, Mueller MM, Fusenig NE, Traupe H, Semmler W. Volumetric computed tomography (VCT): a new technology for noninvasive, high-resolution monitoring of tumor angiogenesis. *Nature Medicine.* 2004;10:1133-1136.
8. Greschus S, Kiessling F, Lichy MP, Moll J, Mueller MM, Savai R, Rose FR, Ruppert C, Günther A, Luecke M, Fusenig NE, Semmler W, Traupe H. Potential Applications of Flat-Panel Volumetric CT in Morphologic and Functional Small Animal Imaging. *Neoplasia.* 2005;8:730-740.
9. Weinand C, Gupta R, Weinberg E, Madisch I, Neville CM, Jupiter JB, Vacanti JP. Toward Regenerating a Human Thumb In Situ. *Tissue Eng Part A.* 2009;9:2605-2615.
10. Obenhauer S, Dullin C, Alves F, Missbach-Guenther J, Grabbe E, Heuser M. Flat-panel-detector-based volumetric CT: performance evaluation of imaging for skeletal structures of small animals in comparison to multislice CT. *Clin Imaging.* 2007;1:18-22.
11. Reichardt B, Sarwar A, Bartling SH, Cheung A, Grasruck M, Leidecker C, Bredalla MA, Brady TJ, Gupta R. Musculoskeletal Applications of flat-panel volume CT. *Skelet Radiol.* 2008;12:1069-1076.



GLOBAL JOURNAL OF MEDICAL RESEARCH: K  
INTERDISCIPLINARY

Volume 15 Issue 2 Version 1.0 Year 2015

Type: Double Blind Peer Reviewed International Research Journal

Publisher: Global Journals Inc. (USA)

Online ISSN: 2249-4618 & Print ISSN: 0975-5888

## Chocolate with High Cocoa Content as a Weight-Loss Accelerator

By Johannes Bohannon, Diana Koch, Peter Homm & Alexander Driehaus

*University Institute of Diet and Health, Germany*

**Abstract- Background:** Although the focus of scientific studies on the beneficial properties of chocolate with a high cocoa content has increased in recent years, studies determining its importance for weight regulation, in particular within the context of a controlled dietary measure, have rarely been conducted.

**Methodology:** In a study consisting of several weeks, we divided men and women between the ages of 19-67 into three groups. One group was instructed to keep a low-carb diet and to consume an additional daily serving of 42 grams of chocolate with 81% cocoa content (chocolate group). Another group was instructed to follow the same low-carb diet as the chocolate group, but without the chocolate intervention (low-carb group). In addition, we asked a third group to eat at their own discretion, with unrestricted choice of food. At the beginning of the study, all participants received extensive medical advice and were thoroughly briefed on their respective diet.

**GJMR-K Classification:** NLMC Code: WS 16



*Strictly as per the compliance and regulations of:*





# Chocolate with High Cocoa Content as a Weight-Loss Accelerator

Johannes Bohannon <sup>α</sup>, Diana Koch <sup>σ</sup>, Peter Homm <sup>ρ</sup> & Alexander Driehaus <sup>ω</sup>

**Abstract- Background:** Although the focus of scientific studies on the beneficial properties of chocolate with a high cocoa content has increased in recent years, studies determining its importance for weight regulation, in particular within the context of a controlled dietary measure, have rarely been conducted.

**Methodology:** In a study consisting of several weeks, we divided men and women between the ages of 19-67 into three groups. One group was instructed to keep a low-carb diet and to consume an additional daily serving of 42 grams of chocolate with 81% cocoa content (chocolate group). Another group was instructed to follow the same low-carb diet as the chocolate group, but without the chocolate intervention (low-carb group). In addition, we asked a third group to eat at their own discretion, with unrestricted choice of food. At the beginning of the study, all participants received extensive medical advice and were thoroughly briefed on their respective diet. At the beginning and the end of the study, each participant gave a blood sample. Their weight, BMI, and waist-to-hip ratio were determined and noted. In addition to that, we evaluated the Giessen Subjective Complaints List. During the study, participants were encouraged to weigh themselves on a daily basis, assess the quality of their sleep as well as their mental state, and to use urine teststrips.

**Result:** Subjects of the chocolate intervention group experienced the easiest and most successful weight loss. Even though the measurable effect of this diet occurred with a delay, the weight reduction of this group exceeded the results of the low-carb group by 10% after only three weeks ( $p = 0.04$ ). While the weight cycling effect already occurred after a few weeks in the low-carb group, with resulting weight gain in the last fifth of the observation period, the chocolate group experienced a steady increase in weight loss. This is confirmed by the evaluation of the ketone reduction. Initially, ketone reduction was much lower in the chocolate group than in the low-carb peer group, but after a few weeks, the situation changed.

The low-carb group had a lower ketone reduction than in the previous period, they reduced 145 mg/dl less ketones, whereas the chocolate group had an average reduction of an additional 145mg/dl.

Effects were similarly favorable concerning cholesterol levels, triglyceride levels, and LDL cholesterol levels of the chocolate group.

Moreover, the subjects of the chocolate group found a significant improvement in their well-being (physically and mentally). The controlled improvement compared to the results of the low-carb group was highly significant ( $p < 0.001$ ).

**Conclusion:** Consumption of chocolate with a high cocoa content can significantly increase the success of weight-loss diets. The weight-loss effect of this diet occurs with a certain delay. Long-term weight loss, however, seems to occur easier and more successfully by adding chocolate. The effect of the chocolate, the so-called "weight loss turbo," seems to go hand in hand with personal well-being, which was significantly higher than in the control groups.

## I. INTRODUCTION

Although there has been an increased focus on the beneficial properties of high cocoa content chocolate in recent years, there are still very few studies concerning its use in weight-loss diets.

A large number of studies have proven the positive health effects of chocolate on the coronary vasculature<sup>1</sup>, insulin secretion<sup>2,3,4</sup> and endothelial function<sup>5,6</sup>. Additionally, the lowering effects of dark chocolate on high blood pressure have already been well documented.<sup>7,8</sup> Moreover, in a systematic review, Ried et al. were able to prove its health benefits and antihypertensive effect.<sup>9</sup>

In terms of nutritional interventions, there have been interesting first attempts with the use of chocolate. In 2012, Golomb et al. showed a connection between regular chocolate consumption and a lower body mass index.<sup>10</sup> However, this study was limited to the mere collection and analysis of chocolate consumption and a possible connection to the BMI.

Moreover, recent research approaches suggest that the selective use of high cocoa content chocolate can also support active weight loss. A long-term study with mice shows that even with a high-fat diet combined with high cocoa content chocolate, the weight of laboratory mice remains low.<sup>11</sup> A similar study with humans has not been published yet.

## II. METHODOLOGY

### a) Study Design

The study is based on the evaluated results of three parallel groups that underwent various dietary interventions in January 2015. They were under medical supervision and were examined at the beginning, divided into groups, instructed, and measured. During the collection period, the participants' data was retrieved in two-day intervals to ensure the regularity of measurement results. In addition to the mere weight loss, there was an emphasis on the documentation of

Author <sup>α</sup> <sup>σ</sup> <sup>ρ</sup> <sup>ω</sup>: Institute of Diet and Health.  
e-mail: johannes@emonk.org



the well-being of the subjects, as this is considered key to long-term weight loss.<sup>12</sup>

#### b) *Study Participants*

To obtain a genuine, non-preselected representation of the general public, the study participants were recruited without further requirements. On average, participants were 29.6 years old and weighed 81.5 kg. Their average BMI was 26.16; the lowest BMI was 19.15, the highest at 39.95.

To represent the disproportionate number of female dieters in the general public, two-thirds of the participants were female, and one-third male.

The participants were healthy or had medical conditions for which a nutrition intervention represents a generally medically accepted form of therapy.

#### c) *Randomization*

After a detailed preliminary, the participants were randomly assigned one medical group from three different batches of diet instructions. For both the study participants and for the authors of this study, the grouping of the participants was unforeseeable.

#### d) *Interventions / Measures*

Participants were assigned to the following groups: low-carb diet plus high cocoa content chocolate (chocolate group), low-carb diet (low-carb group), and the control group.

The participants of the chocolate group were told to eat as many low-carbohydrate foods as possible, and to increase the protein and fat content of their diet. Additionally, they were given 875 grams of chocolate with a cocoa content of 81 percent. They were asked to consume a daily dose of 42 grams of chocolate in addition to the low-carb diet. Over a period of three weeks, 100 percent of the subjects adhered to this requirement.

The participants of the low-carb group were instructed to change their diet to a low-carbohydrate diet. Concerning the diet, their instructions were absolutely identical with those of the chocolate group.

Nutrition interventions that apply a low-carbohydrate diet are currently the most applied approach to a weight-loss diet, which is particularly recommended in the S3-guidelines on "Prevention and Treatment of Obesity."<sup>13</sup>

Participants in the control group were encouraged to continue their previous eating habits. It should be noted that the study was conducted in early January, after the Christmas / New Year celebrations.

#### e) *Testing Methods*

In addition to the continuous measurement of weight development, participants were asked to do routine testing of the urine with multiparameter strips on a daily basis by using test strips, and to document their mental state and their sleep behavior.

At the beginning and end of the study, a blood test was conducted; weight, BMI, and waist-to-hip ratio were documented; and the Giessen Subjective Complaints List, which measures the change in well-being on a scientifically sound basis, was evaluated.<sup>14</sup>

The main focus within the blood parameters was on the changes in lipid levels and liver values, as well as the possible increased amount of protein in the blood. Previous studies have shown that a unilateral low-carb diet can lead to some dramatic changes in the albumin value.<sup>15</sup> Concerning the evaluations, we took into consideration changes of cholesterol, triglycerides, LDLcholesterol, ALT, GGT/GGTP, and the albumin.

Additionally, we observed the changes of ketone reduction in urine.

#### f) *Statistics*

A t-test for independent samples was used to assess differences in baseline variables between the groups. The analysis was a repeated-measures analysis of variance in which the baseline value was carried forward in the case of missing data. One subject (low-carbohydrate) had to be excluded from the analysis, because of a weight measure issue within the trial.

### III. RESULTS

#### a) *Weight Development*

Both the participants of the chocolate group and the low-carb group lost weight, whereas the control group gained weight during the study period. The subjects of the low-carb group lost 3.1 percent of their body weight in 21 days and the chocolate group lost 3.2 percent. The participants of the control group were on average 0.7 percent heavier. The body mass index decreased in the chocolate group to 0.93, in the low-carb intervention group by 0.95 points, whereas the control group gained 0.7 points.




Figure 1 : Daily weight development by group

Remarkably, participants in the chocolate group lost more weight than those of the low-carb group. The temporal course of the weight-loss success is also worth noting: the course of the intervention period shows that there were marked differences in both groups. While the low-carb group lost weight from the beginning and continued this weight loss during the first three quarters of the testing period, the chocolate group

gained weight in the first quarter before they started to lose considerably more weight than the low-carb group.

In the third quarter, the weight-loss ratio of the low-carb group came to its minimum, while the chocolate group lost considerably more weight during the third consecutive quarter than prior, and significantly more than both of the control groups combined.





Figure 2 : Cumulated change of weight by test group

#### b) Ketones

A higher amount of ketones could be detected in the participants of the chocolate group than in the low-carb group. The measured results were found to be highly significant ( $p < 0.01$ ).



### c) Lipid Levels

Cholesterol levels as well as triglycerides and LDL cholesterol concentrations improved significantly in participants of the chocolate group in comparison to the low-carb group.

### d) Liver Values

Participants of the chocolate group also showed the most significant changes in ALT and GGT/GGTP values.

### e) Albumin

While the measured urinary protein breakdown increased significantly in the low-carb group, the proportion in the chocolate group increased by only one-sixth. At the end of the testing period, the protein detected in the control group's urine was lower than the initially measured values.

**Table 1 : Absolute changes in lipid levels, liver values, and albumin values in an analysis that include data on all subjects in the relevant groups.**

Variable	Chocolate Diet		Low-Carbohydrate		P-Value
Cholesterol (mg/dl)					
Day 21	-12,2	± 26,7	2,3	± 15,9	0,19
Triglycerides (mg/dl)					
Day 21	-22,6	± 85,7	3,0	± 41,3	0,55
LDL cholesterol (mg/dl)					
Day 21	-17,4	± 22,8	-5,0	± 22,4	0,00
ALT (U/l)					
Day 21	-6,4	± 6,7	-11,5	± 3,6	0,11
GGT/GGTP (U/l)					
Day 21	-8,8	± 5,5	-2,0	± 0,0	0.23
Albumin (g/dl)					
Day 21	0,0	± 0,4	0,1	± 0,3	0.23


Plus-minus values are means ±. The chocolate group had 5 subjects, in the low-carbohydrate group only 4 subjects could be considered.

P values are for the differences between the two groups.

### f) Giessen Subjective Complaints List

We also found highly significant differences with regard to physical and psychological ailments, which we obtained with the help of the Giessen Subjective Complaints List. Although the perception in the low-carb

group and control group did not change by much, the participants of the chocolate group felt much better on average. Exhaustion symptoms in particular, such as fatigue or the sensation of heavy legs, significantly decreased in the chocolate group. The significance of this survey was  $p < 0.001$ .



**Figure 4 : Analysis of Giessen Subjective Complaints List - Development during the trial period**

#### IV. CONCLUSION

The results of this study show that the addition of high cocoa content chocolate can actually be used as a supportive measure in nutritional interventions. However, the focus should not remain on the slightly greater weightloss of the chocolate group compared to the low-carb group, but on the weight development.

High cocoa content chocolate could be the key to solving the biggest problem of all nutritional interventions. "Weight cycling" is, for example, associated with increased bone loss ratio in the hip and the lumbar area, and with an increased risk for loss of bone density.<sup>16</sup>

Moreover, several studies have shown additional risks of significant weight gain (increased risk of cardiovascular and all-cause mortality, of hypertension in obese women, and symptomatic gallstones in men).<sup>17,18,19,20</sup>

Many weight-loss diets share the common factor of weight gain within several months after a short

and often significant weight reduction. This applies to almost all of the weight-loss programs recommended by the Deutsche Adipositasgesellschaft. In studies focusing on the *Weight Watchers* program, participants in the commercial program gained back weight after the 26th week.<sup>21</sup> In a study of the medical outpatient intervention program *Bodymed*, Walle et al. found that the continuous slimming effect of the mean body weight also stopped after 26 weeks.<sup>22</sup> The same applies to the OPTI FAST program.<sup>23</sup>

In 2003, Foster et al. proved in their groundbreaking, randomized study on a low-carb diet that the effect of weight reduction or greater weight loss compared to a low-fat intervention is not significantly detectable after one year.<sup>24</sup>

Consequently, the weight gain of the low-carb group in this study is in line with previous research. The different weight development course of the chocolate group is therefore all the more impressive. Remarkably, "weight cycling" is not detectable in this group. The initial slight weight gain is currently inexplicable to us. It may

be related to the body's response to the flavanols or to other factors that were not the focus of this study. However, it is more important to consider the blood and fat levels. Thus, the values of the chocolate group on average improved not only considerably more than those of the low-carb group, but they even resulted in better LDL levels after just three weeks compared to levels participants reached after three months in diet groups graded by the professional associations with the quality level S3 (highest stage) and the recommendation grade A (the highest level).

The albumin values of the study participants are also worth mentioning. Criticism of low-carb diets always broaches the issue of excessive protein intake. One suspects that this may lead to an increased risk of coronary artery disease.<sup>25</sup>

Unlike the participants in the low-carb group, however, the chocolate group showed hardly any increase of albumin degradation. It was lower by a factor of 6. The risk for coronary heart disease should therefore be much lower.

Considering all of these results, it is not surprising that the chocolate group participants felt significantly better than those in the other two groups. Therefore, we recommend the consumption of high cocoa content chocolate during nutritional interventions. The positive effects that have been proven in laboratory mice seem to be relevant to humans.

The authors of this study believe that high cocoa content chocolate is therefore an ideal "weight-loss turbo" if used in combination with a low-carb intervention for weight loss.

Further studies should examine the suitability of this highly efficient weight-loss accelerator for other intervention programs.

1. Allen RR, Carson LA, Kwik-Urbe C, Evans EM, Erdman JW Jr. Daily consumption of a dark chocolate containing flavanols and added sterol esters affects cardiovascular risk factors in a normotensive population with elevated cholesterol. *J Nutr.* 2008; 728: 725–731.
2. McCullough ML, Chevaux K, Jackson L, Preston M, Martinez G, Schmitz HH, Coletti C, Campos H, Hollenberg NK. Hypertension, the Kuna, and the epidemiology of flavanols. *J Cardiovasc Pharmacol.* 2006; 47: S103–S109.
3. Taubert D, Roesen R, Schömig E. Effect of cocoa and tea intake on blood pressure. *Arch Intern Med.* 2007; 167: 626–634.
4. Grassi D, Lippi C, Necozione S, Desideri G, Ferri C. Short-term administration of dark chocolate is followed by a significant increase in insulin sensitivity and a decrease in blood pressure in healthy persons. *Am J Clin Nutr.* 2005; 81: 611–614.
5. Engler MB, Engler MM, Chen C-Y, Malloy MJ, Browne A, Chiu EY, Kwak H-K, Milbury P, Paul SM, Blumberg J, Mietus-Snyder ML. Flavanoid-rich dark chocolate improves endothelial function and increases plasma epicatechin concentrations in healthy adults. *J Am Coll Nutr.* 2004; 23: 197–204.
6. Davison K, Coates AM, Buckley JD, Howe PRC. Effect of cocoa flavanols and exercise on cardiometabolic risk factors in overweight and obese subjects. *Int J Obes.* 2008; 32: 1289–1296.
7. Egan BM, Papademetriou V, Wofford M, Calhoun D, Fernandez J, Riehle JE, Nesbitt S, Julius S. Metabolic syndrome and insulin

7. Egan BM, Papademetriou V, Wofford M, Calhoun D, Fernandez J, Riehle JE, Nesbitt S, Julius S. Metabolic syndrome and insulin resistance: Contrasting views in patients with high normal blood pressure. *Am J Hypertens.* 2005; 18: 3–12.
8. Corti R, Flammer AJ, Hollenberg NK, Lüscher TF. Cocoa and cardiovascular health. *Circulation.* 2009; 119: 1433–1441.
9. Ried K, Sullivan TR, Fakler P, Frank OR, Stocks NP. Effect of cocoa on blood pressure. 2012, The Cochrane Library.
10. Golomb BA, Koperski S, White HL. Association Between More Frequent Chocolate Consumption and Lower Body Mass Index. *Arch Intern Med.* 2012;172(6):519–521.
11. Dorenkott MR, Griffin LE, Goodrich KM, et al. Oligomeric Cocoa Procyanidins Possess Enhanced Bioactivity Compared to Monomeric and Polymeric Cocoa Procyanidins for Preventing the Development of Obesity, Insulin Resistance, and Impaired Glucose Tolerance during High-Fat Feeding. *J. Agric. Food Chem.* 2014, 62 (10), pp 2216–2227.
12. Blaine BE, Rodman J, Newman JM. Weight Loss Treatment and Psychological Well-being: A Review and Meta-analysis. *J Health Psychol* January 2007 12: 66–82.
13. Wabitsch M, Wirth A, Hauner H, et al. Interdisziplinäre Leitlinie der Qualität S3 zur „Prävention und Therapie der Adipositas. 2014, Deutsche Adipositas Gesellschaft.
14. Brähler E, Hinz A, Scheer JW. GBB-24. Der Gießener Beschwerdebogen. Manual. 2008, Bern.
15. Lagiou P, Sandin S, Lof M, Trichopoulos D, Adami HO, Weiderpass E. Low carbohydrate-high protein diet and incidence of cardiovascular diseases in Swedish women: prospective cohort study. *BMJ* 2012;344:e4026.
16. Papaioannou A, Kennedy CC, Cranney A, Hawker G, Brown JP, Kaiser SM, Leslie WD,
17. O'Brien CJ, Sawka AM, Khan A, Siminoski K, Tarulli G, Webster D, McGowan J, Adachi JD. Risk factors for low BMD in healthy men age 50 years or older: a systematic review. *Osteoporosis Int* 2009;20(4):507–18.
18. Diaz VA, Mainous AG, III, Everett CJ. The association between weight fluctuation and mortality: results from a population-based cohort study. *J Community Health* 2005;30(3):153–65.
19. Guagnano MT, Ballone E, Pace-Palitti V, Vecchia RD, D'Orazio N, Manigrasso MR, Merlitti D, Sensi S. Risk factors for hypertension in obese women. The role of weight cycling. *Eur J Clin Nutr* 2000;54(4):356–60.
20. Rzehak P, Meisinger C, Woelke G, Brasche S, Strube G, Heinrich J. Weight change, weight cycling and mortality in the ERFORT Male Cohort Study. *Eur J Epidemiol* 2007;22(10):665–73.
21. Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Weight cycling and risk of gallstone disease in men. *Arch Intern Med* 2006;166(21):2369–74.
22. Heshka S, Anderson JW, Atkinson RL, Greenway FL, Hill JO, Phinney SD, Kolotkin RL, Miller-Kovach K, Pi-Sunyer FX. Weight Loss With Self-help Compared With a Structured Commercial Program. *JAMA.* 2003;289(14):1792–1798.
23. Becker C, Walle H. Ärztlich betreut, ambulant gegen Adipositas. *Aktuel Ernährungsmed* 2014; 39(04): 256–269.
24. Wechsler G, Bischoff G, Hagen H, Bischoff M. Adipositastherapie mit Formuladiäten. 2011; 5(2): 89–94.
25. Foster GD, Wyatt HR, Hill JO, McGuckin BG, Brill C, Mohammed BS, Szapary PO, Rader DJ, Edman JS, Klein S. A Randomized Trial of a Low-Carbohydrate Diet for Obesity. *N Engl J Med* 2003; 348:2082–2090.
26. Lagiou P, Sandin S, Lof M, Trichopoulos D, Adami HO, Weiderpass E. Low carbohydrate-high protein diet and incidence of cardiovascular diseases in Swedish women: prospective cohort study. *BMJ* 2012;344:e4026.



GLOBAL JOURNAL OF MEDICAL RESEARCH: K  
INTERDISCIPLINARY

Volume 15 Issue 2 Version 1.0 Year 2015

Type: Double Blind Peer Reviewed International Research Journal

Publisher: Global Journals Inc. (USA)

Online ISSN: 2249-4618 & Print ISSN: 0975-5888

## Quality of Life Comparison in Chronic Pancreatitis Patients: A Case-Control Study

Samuel Han, Joan Kheder, Julien Fahed, Lisa Bocelli, Yoel Carrasquillo, Amy Waccholtz & Wahid Wassef

*University of Massachusetts Medical School, United Kingdom*

**Abstract- Introduction:** Chronic pancreatitis presents a significant problem to healthcare practitioners as it affects many areas of a patient's health, including their physical, mental, and socioeconomic health. The Pancreatitis Quality of Life Instrument (PANQOLI) is the 1st instrument developed specifically to evaluate the quality of life of patients with chronic pancreatitis. This study compares a healthy control population with a chronic pancreatitis population using the PANQOLI to provide a normal distribution curve.

**Methods:** 56 patients with chronic pancreatitis were given the PANQOLI and compared with 52 healthy individuals (consisting of medical students and residents) who also completed the PANQOLI. Subgroup analysis was also performed to compare smokers and non-smokers, as well as malnourished and non-malnourished patients.

**GJMR-K Classification:** NLMC Code: WI 805



QUALITY OF LIFE COMPARISON IN CHRONIC PANCREATITIS PATIENTS: A CASE CONTROL STUDY

*Strictly as per the compliance and regulations of:*





# Quality of Life Comparison in Chronic Pancreatitis Patients: A Case-Control Study

Samuel Han<sup>α</sup>, Joan Kheder<sup>σ</sup>, Julien Fahed<sup>ρ</sup>, Lisa Bocelli<sup>ω</sup>, Yoel Carrasquillo<sup>χ</sup>, Amy Waccholtz<sup>§</sup>  
& Wahid Wassef<sup>x</sup>

**Abstract- Introduction:** Chronic pancreatitis presents a significant problem to healthcare practitioners as it affects many areas of a patient's health, including their physical, mental, and socioeconomic health. The Pancreatitis Quality of Life Instrument (PANQOLI) is the 1st instrument developed specifically to evaluate the quality of life of patients with chronic pancreatitis. This study compares a healthy control population with a chronic pancreatitis population using the PANQOLI to provide a normal distribution curve.

**Methods:** 56 patients with chronic pancreatitis were given the PANQOLI and compared with 52 healthy individuals (consisting of medical students and residents) who also completed the PANQOLI. Subgroup analysis was also performed to compare smokers and non-smokers, as well as malnourished and non-malnourished patients.

**Results:** The chronic pancreatitis group scored significantly lower than the control group on the PANQOLI (56.2 vs. 92.3,  $p < 0.0001$ ), with a lower PANQOLI score representing a worse quality of life. Within the chronic pancreatitis group, smokers had a lower PANQOLI score than non-smokers (52.8 vs. 60.1,  $p < 0.05$ ), while there was no difference between malnourished patients and non-malnourished patients (55.1 vs. 58.5,  $p < 0.46$ ).

**Discussion:** This study presents the 1st evaluation of a chronic pancreatitis population using the PANQOLI in comparison to a healthy population. As expected, the chronic pancreatitis population had a worse quality of life as did smokers compared to non-smokers, highlighting the potential use of the PANQOLI to objectively assess the impact of interventions in these patient groups.

## I. INTRODUCTION

Chronic pancreatitis presents a significant medical problem to healthcare practitioners as it affects many aspects of a patient's health and has been found to be associated with a poor quality of life.<sup>1-2</sup> A global problem, worldwide prevalence has been estimated to range from 3-20%.<sup>3-6</sup> Most often caused by alcohol consumption, chronic pancreatitis may also be caused by metabolic disorders (hyperlipidemia and hypercalcemia), and genetic disorders (including Cystic Fibrosis, SPINK, cationic trypsinogen mutations) 4. Characterized by progressive inflammatory changes in the pancreas, chronic pancreatitis often causes

abdominal pain and symptoms of pancreatic insufficiency, such as steatorrhea and diabetes, are the predominant features of this disease. Studies have demonstrated the increased burden of chronic pancreatitis in areas such as physical health, most notably in pain, nutritional status, and diarrhea.<sup>1-2</sup> Other areas affected include financial factors such as unemployment or early retirement, as well as mental health factors.<sup>2</sup> The socioeconomic burden has been found to be increasing as management of chronic pancreatitis entails the cost of admissions, the cost of pancreatic insufficiency, the cost of pain, and the cost of interventions, among other costs.<sup>8</sup> This has been estimated to cost around \$638 million a year.<sup>8</sup> Furthermore, complications can include pseudocyst formation, pancreatic ascites, splenic vein thromboses, and pancreatic cancer.<sup>9</sup> All these features combine to play a large role in altering the quality of life of these patients.<sup>2,10,11</sup>

To better manage patients with chronic pancreatitis and address patient-specific issues, an instrument called the Pancreatitis Quality of Life Instrument (PANQOLI) was developed.<sup>12</sup> This instrument consists of 18 questions, and provides a comprehensive measure of quality of life measures. Validated in two separate studies involving over 300 patients in eleven clinical sites, the PANQOLI has shown excellent reliability and construct validity.<sup>13,14</sup> This instrument represents the 1st disease-specific instrument created for evaluating quality of life in patients with chronic pancreatitis and has been utilized extensively at our institution since its inception.

This study reports the initial evaluation of the PANQOLI at our institution on patients with chronic pancreatitis compared to other control patients in order to help provide a normal distribution curve that can be applied as a standard for future use of the instrument.

## II. METHODS

The PANQOLI was administered to 56 patients previously diagnosed with chronic pancreatitis who regularly follow-up at our chronic pancreatitis clinic. The same instrument was given to a control population consisting of 52 individuals. The PANQOLI results were then compared between the groups. Subgroup analysis was also performed to compare smokers and non-

Author<sup>α</sup> <sup>σ</sup> <sup>ρ</sup> <sup>ω</sup> <sup>χ</sup> : Department of Gastroenterology. University of Massachusetts Medical School. 55 Lake Avenue North. Worcester, MA 01655. e-mail: samuel.han@umassmemorial.org

Author <sup>§</sup> : Department of Psychiatry. University of Massachusetts Medical School. 55 Lake Avenue North. Worcester, MA 01655.

smokers, as well as malnourished and non-malnourished.

#### a) Subjects

Patients with chronic pancreatitis required a diagnosis by either the presence of pancreatic calcifications on CT (Computed Tomography) scan or KUB (kidney, ureter, and bladder) imaging or the presence of 5 out of 9 criteria of pancreatic injury by

endoscopic ultrasound (Please see Table 1 for further inclusion and exclusion criteria). Institutional Review Board (IRB) approval of the study was obtained and patients who met the inclusion/exclusion criteria were asked during a regularly scheduled visit if they wished to participate in this study. Subjects were then asked to sign an informed consent if they agreed to participate.

*Table 1 : Inclusion - exclusion criteria for chronic pancreatitis patients*

Inclusion criteria	Exclusion criteria
<p>Patient must have abdominal pain, not related to other identifiable etiologies in conjunction with one of the following two features:</p> <p>(a) Presence of pancreatic calcification as demonstrated by an imaging study such as CT scan or KUB imaging</p> <p>(b) Presence of five out of nine criteria of pancreatic injury by endoscopic ultrasound in conjunction with a positive secretin stimulation test to confirm pancreatic insufficiency.</p>	<p>Patient to be excluded from the study if they have one of the following features:</p> <p>(a) Age less than 18 years</p> <p>(b) Comorbidities such as end-stage cancer (estimated survival &lt; 6 months), HIV (T4 cell count &lt; 50), end-stage congestive heart failure, end-stage chronic obstructive pulmonary disease, uncompensated cirrhosis, renal failure (on dialysis or with CrCl &lt;25), or pre-existing diabetes mellitus</p> <p>(c) Non-English speaking</p>

*CT: computed tomography; KUB: kidney, ureter, and bladder; CrCl: creatinine clearance*

The control population consisted of a relatively healthy group of subjects consisting of medical students and residents at our institution who do not have chronic pancreatitis. Informed consent was obtained if the subject agreed to participate in the study.

Demographic data collected included age, gender, race, smoking status, opiate use, and endoscopic ultrasound (EUS) characterization of disease severity.

#### b) Sub-Groups

Within the chronic pancreatitis population, patients were identified as smokers if they reported that they were active smokers. In terms of identifying malnourished patients, patients regularly followed at our clinic were routinely asked to fill out a Malnutrition Universal Screening Tool (MUST).<sup>15</sup> Those patients scoring >2 were defined as being malnourished.

#### c) Statistics

Multivariate analysis was performed utilizing the Anova test and power was calculated to be 80%.

Analysis was performed using SPSS software (IBM SPSS Version 21.0).

### III. RESULTS

A total of 56 patients in the chronic pancreatitis group and 52 patients in the control group participated in this study. The mean score of the PANQOLI in the chronic pancreatitis group was 56.2, compared to 92.3 in the control group, which was highly significant ( $p<0.0001$ ) adjusting for age, race, gender, and smoking status, with a higher score representing a better quality of life. In terms of the sub-groups within the chronic pancreatitis group, smokers ( $n=30$ ) had a mean score of 52.8 in comparison to non-smokers ( $n=26$ ), who had a mean score of 60.1 ( $p<0.05$ ), accounting for age, race, gender, opiate use, and EUS grading. In comparing by nutritional status, malnourished ( $n=18$ ) patients had a mean of 55.1, while the non-malnourished ( $n=38$ ) had a mean of 58.5, which was not significant ( $p<0.46$ ). Please see Tables 2-4.

*Table 2 : Comparison of chronic pancreatitis group with control group*

Category	Chronic Pancreatitis Group (n=56)	Control Group (n=52)	p-value
Age (years)	48.7 $\pm$ 9.2	30 $\pm$ 4.1	$p<0.0001$
Gender	36 Female 20 Male	28 Females 24 Males	$p<0.18$
Race	49 Caucasian 5 Black 2 Hispanic	36 Caucasian 7 Asian 5 Indian 3 Hispanic 1 Black	$p<0.025$
Tobacco Use	30 Smokers 26 Non-smokers	1 Smoker 51 Non-Smokers	$p<0.0001$

Opiate Use (mg of oral morphine/day)	125.4 ± 101.2	0	p<0.0001
EUS Grading of CP	Mild (28.6%) Mild-Moderate (7.1%) Moderate (48.2%) Moderate-Severe (5.4%) Severe (10.7%)	N/A	N/A
PANQOLI Mean Score	56.2 ± 14.6	92.3 ± 0.8	p<0.0001

EUS: endoscopic ultrasound; CP: Chronic Pancreatitis; PANQOLI: PANcreatitis Quality Of Life Instrument

**Table 3 : Comparison of smokers with non-smokers**

Category	Smoker (n=30)	Non-Smoker (n=26)	p-value
Age	45.8 ± 8.9	52.0 ± 8.6	p<0.01
Gender	Male (26.7%) Female (73.3%)	Male (46.2%) Female (53.8%)	p < 0.13
Race	Caucasian (93.3%) Black (6.7%)	Caucasian (80.8%) Black (11.5%) Hispanic (7.7%)	p < 0.23
Opiate Use (mg of oral morphine/day)	135 ± 93.9	114.3 ± 109.9	p < 0.45
EUS Grading of CP	Mild (33.3%) Mild-Moderate (6.7%) Moderate (43.3%) Moderate-Severe (6.7%) Severe (10%)	Mild (32.1%) Mild-Moderate (7.7%) Moderate (53.8%) Moderate-Severe (3.8%) Severe (11.6%)	p<0.90
PANQOLI mean score	52.8 ± 11.9	60.1 ± 16.5	p<0.05

EUS: endoscopic ultrasound; CP: Chronic Pancreatitis; PANQOLI: PANcreatitis Quality Of Life Instrument

**Table 4 : Comparison of malnourished with non-malnourished subjects**

Category	Malnourished (n=18)	Non-malnourished (n=38)	p-value
Age (years)	50.6 ± 7.0	47.7 ± 10.1	p < 0.28
Gender	Male (33.3%) Female (66.7%)	Male (36.8%) Female (63.2%)	p < 0.80
Race	Caucasian (83.3%) Black (11.1%) Hispanic (5.6%)	Caucasian (89.5%) Black (7.9%) Hispanic (2.6%)	p < 0.78
Opiate Use (mg of oral morphine/day)	132.5 ± 110.1	122 ± 98.1	p < 0.72
EUS Grading of CP	Mild (34.2%) Mild-Moderate (7.9%) Moderate (42.1%) Moderate-Severe (2.6%) Severe (13.2%)	Mild (16.7%) Mild-Moderate (5.6%) Moderate (61.1%) Moderate-Severe (11%) Severe (5.6%)	p < 0.11
PANQOLI mean score	58.5 ± 16.9	55.1 ± 13.5	p<0.46

EUS: endoscopic ultrasound; CP: Chronic Pancreatitis; PANQOLI: PANcreatitis Quality Of Life Instrument

In terms of demographic data, there were significant differences between the chronic pancreatitis group and the control group. The control group was significantly younger, more racially diverse, and had far less narcotic and tobacco use (Table 2). Within the sub-groups, the only significant demographic difference was in the smoker group, who had a significantly younger mean age (45.8) compared to the non-smoking group (52). Please see tables 2-4.

#### IV. DISCUSSION

This study presents an initial evaluation of the PANQOLI in chronic pancreatitis patients at a single

tertiary medical center. Quality of life in chronic pancreatitis patients was most notably evaluated in the North American Pancreatitis Study 2 (NAPS 2), which evaluated 540 patients with chronic pancreatitis. 16 443 of the 540 patients completed the Short Form-12 (SF-12), a instrument used commonly to evaluate quality of life, which gives a physical component and a mental component score. The NAPS 2 study found lower physical and mental component scores in the chronic pancreatitis group compared to a control population, which was consistent with other chronic diseases.<sup>17</sup> The SF-12, however, is not a disease-specific instrument

and primarily assesses the limiting effects of a disease. As quality of life entails a vast amount of factors such as depression, sleep, coping skills, and financial repercussions, the PANQOLI was developed to quickly assess in a single instrument the overall quality of life of patients with chronic pancreatitis.

As expected, this study revealed a significant difference in PANQOLI scores between the chronic pancreatitis population and the control population. The control population scored significantly higher, implying a higher quality of life, which is consistent with a healthy population. Furthermore, in terms of the sub-group analysis, there was a significant difference in PANQOLI scoring between the smoking and non-smoking groups. The non-smoking group scored higher on the PANQOLI than their counterparts which is not surprising considering that smoking would be expected to worsen quality of life.<sup>18-20</sup>

The main limitation of this study is the control group in this study, which consisted of medical students and residents. While this group represented a younger population with relatively few co-morbidities, it did not guarantee a healthy population.

In summary, this prospective study describes the initial use of the PANQOLI in a chronic pancreatitis population in an attempt to create a normal distribution. While displaying that these patients have a poorer quality of life compared to a control population, it also displayed worse quality of life in patients who smoke. This invites further studies to be done to evaluate quality of life differences in this sub-group and hints at the possibility of therapeutic interventions addressing this risk factor. In line with this, further validation of the PANQOLI may also allow for objective assessment of the holistic impact of interventions in this disease process using the PANQOLI.

## REFERENCES RÉFÉRENCES REFERENCIA

1. Wehler, M, Reulbach U, Nichterlein R, et al. Health-related quality of life in chronic pancreatitis: a psychometric assessment. *Scandinavian Journal of Gastroenterology* 2003; 38(10): 1083–1089.
2. Wehler M, Nichterlein R, Fischer B, et al. Factors associated with health-related quality of life in chronic pancreatitis. *Am J Gastroenterol* 2004; 99(1): 138–146.
3. Yadav D and Lowenfels A. The epidemiology of pancreatitis and pancreatic cancer. *Gastroenterology* 2013; 144(6): 1252-1261.
4. Yadav D, Eigenbrodt M, Briggs M, et al. Pancreatitis: prevalence and risk factors among male veterans in a detoxification program. *Pancreas* 2007; 34(4): 390-398.
5. Maruyama K and Otsuki M. Incidence of alcoholic pancreatitis in Japanese alcoholics: survey of male sobriety association members in Japan. *Pancreas* 2007; 34(1): 63-65.
6. Garg P and Tandon R. Survey on chronic pancreatitis in the Asia-Pacific region. *J Gastroenterol Hepatol* 2004; 19(9): 998-1004.
7. Steer ML, Waxman I, Freedman S. Chronic pancreatitis. *N Engl J Med* 1995; 332:1482.
8. Hall TC, Garcea G, Webb MA, Al-Leswas D, Metcalfe MS, Dennison AR. The socio-economic impact of chronic pancreatitis: a systematic review. *J Eval Clin Pract.* 2014 Jun; 20(3):203-7.
9. Ammann RW, Akovbiantz A, Largiader F, Schueler G. Course and outcome of chronic pancreatitis. Longitudinal study of a mixed medical-surgical series of 245 patients. *Gastroenterology* 1984; 86:820.
10. Gardner T, Kennedy A, Gelrud A, et al. Chronic pancreatitis and its effects on employment and health care experience: results of a prospective American multicenter study. *Pancreas* 2010; 39(4): 498–501.
11. Mokrowiecka A, Pinkowski D, Malecka-Panas E, et al. Clinical, emotional and social factors associated with quality of life in chronic pancreatitis. *Pancreatology* 2010; 10(1): 39–46.
12. Wassef W, Bova C, Barton B, Hartigan C. Pancreatitis Quality of Life Instrument: Development of a new instrument. *SAGE Open Medicine* 2014; 2: 2050312114520856.
13. Wassef W, Bova C, Barton B, Hartigan C. Pancreatitis Quality of Life Instrument (PANQOLI): Validation of the Electronic Version. Abstracts of Papers Submitted to the 44th Meeting of the American Pancreatic Association, October 30–November 2, 2013, Miami, Florida. *Pancreas* 2013; 42(8): 1388. Doi:10.1097/Mpa.0b013e3182a9753b.
14. Wassef W, De Witt J, Wilcox M, Whitcomb D, Et Al. Pancreatitis Quality Of Life Instrument (PANQOLI): A Psychometric Evaluation. *Pancreatic/Biliary. The American Journal Of Gastroenterology* 2012; 107: S79-S80. Doi:10.1038/Ajg.2012.269.
15. Elia M Chairman And Editor (2003) Screening For Malnutrition: A Multidisciplinary Responsibility. Development And Use Of The 'Malnutrition Universal Screening Tool' ('MUST') For Adults. Malnutrition Advisory Group (MAG), A Standing Committee Of BAPEN. Redditch, Worcs.: BAPEN.
16. Whitcomb DC, Yadav D, Adam S, et al. Multicenter approach to recurrent acute and chronic pancreatitis in the United States: the North American Pancreatitis Study 2 (NAPS2). *Pancreatology.* 2008;8:520Y531.
17. Amman ST, Yadav D, Barmada MM, et al. Physical and mental quality of life in chronic pancreatitis: a case-control study from the North American

Pancreatitis Study 2 cohort. *Pancreas* 2013; 42(2): 293-300.

18. Coté GA, Yadav D, Slivka A, et al. Alcohol and smoking as risk factors in an epidemiology study of patients with chronic pancreatitis. *Clin Gastroenterol Hepatol* 2011; 9:266.
19. Yadav D, Hawes RH, Brand RE, et al. Alcohol consumption, cigarette smoking, and the risk of recurrent acute and chronic pancreatitis. *Arch Intern Med* 2009; 169:1035.
20. DiMagno EP, Go VL, Summerskill WH. Relations between pancreatic enzyme outputs and malabsorption in severe pancreatic insufficiency. *N Engl J Med* 1973; 288:813.





This page is intentionally left blank





GLOBAL JOURNAL OF MEDICAL RESEARCH: K  
INTERDISCIPLINARY

Volume 15 Issue 2 Version 1.0 Year 2015

Type: Double Blind Peer Reviewed International Research Journal

Publisher: Global Journals Inc. (USA)

Online ISSN: 2249-4618 & Print ISSN: 0975-5888

## Comparing Health Indicators: Colombia and the OECD

By Oscar Bernal, Diana Zamora, Carlos Grijalba & Anna Spector

*University of Andes, Colombia*

**Abstract-** Colombia has shown its intention to enter the OECD and during this process, it is important to compare its health indicators with the OCDE's countries, taking in account not only the average results, but the differences according to regions, sex, ethnicity and income.

The methodology uses has been based on the OECD framework with a broad view of public health, including health status, non-medical determinants of health, health workforce, health care, quality of care, access to care, health expenditure, ageing and long-term care.

The main achievements of Colombia are universal coverage and low out-of-pocket payments. Colombia has some opportunities to show better health indicators due to a younger population, lower rates of diabetes and overweight and a low suicide rate compared with OECD countries.

**Keywords:** *health indicators, OECD, colombia, morbidity.*

**GJMR-K Classification:** *NLMC Code: W 84*



*Strictly as per the compliance and regulations of:*



# Comparing Health Indicators: Colombia and the OECD

Oscar Bernal <sup>α</sup>, Diana Zamora <sup>σ</sup>, Carlos Grijalba <sup>ρ</sup> & Anna Spector <sup>ω</sup>

**Abstract-** Colombia has shown its intention to enter the OECD and during this process, it is important to compare its health indicators with the OCDE's countries, taking in account not only the average results, but the differences according to regions, sex, ethnicity and income.

The methodology uses has been based on the OECD framework with a broad view of public health, including health status, non-medical determinants of health, health workforce, health care, quality of care, access to care, health expenditure, ageing and long-term care.

The main achievements of Colombia are universal coverage and low out-of-pocket payments. Colombia has some opportunities to show better health indicators due to a younger population, lower rates of diabetes and overweight and a low suicide rate compared with OECD countries. Colombia needs to improve on equality by region, education and income, access and quality of care, mental health services, plus needs to reduce preventable mortality due to violence.

**Keywords:** *health indicators, OECD, colombia, morbidity.*

## I. INTRODUCTION

The Organization for Cooperation and Economic Development (OECD) is comprised of 34 countries around the world. Since 2010 Colombia has shown its intention to enter the OECD, with a formal request by President Santos and followed by a visit to the OECD. Admission to the OECD will allow the country to benefit from the work and experience in the formulation of public policy of the leading economies in the world (Ministerio Hacienda, 2012).

The Colombian Government will also have the opportunity to influence the design and adjustments of key instruments and initiatives to improve the functioning of the global economy and global governance (Gurria, 2013). OECD believes that the inclusion of Colombia is more a process than an event (OCDE, 2012) and as part of the process; the OECD will evaluate the application by Colombia of policies, practices and the legal instruments of the organization.

The OECD's report, Health at Glance, 2013, showed improvement in life expectancy and infant mortality, however inequalities in wealth, education and other social indicators still have a significant impact on health status (OCDE, 2013).

**Author <sup>α σ ρ</sup> :** Universidad de los Andes.

**e-mails:** [obernal@uniandes.edu.co](mailto:obernal@uniandes.edu.co), [dc.zamora35@uniandes.edu.co](mailto:dc.zamora35@uniandes.edu.co), [ca.grijalba961@uniandes.edu.co](mailto:ca.grijalba961@uniandes.edu.co)

**Author <sup>ω</sup> :** Pontificia Universidad Javeriana.

**e-mail:** [aspector@javeriana.edu.co](mailto:aspector@javeriana.edu.co)

Colombia and the OECD countries share common challenges such as the ageing of the population, an increase of non-communicable diseases, users who expect better treatments, and the exponential increase of health technology and pharmaceuticals. In some indicators Colombia has a lot to learn and work on to reach the average OECD level and in others Colombia has lessons learned to share with the OECD.

The goal of this analysis is to compare Colombian and OECD indicators, taking in account not only the average results, but the differences according to regions, ethnicity and income. Some of the data from the individual report providing health services has a 50% of under-reporting (ONS, 2014).

## II. METHODOLOGY

We use the oecd framework with a broad view of public health including determinants of health and the OECD health care quality indicators project (kelley, 2006).

We follow the same components of the OECD health analysis (OCDE, 2013), including health status, non-medical determinants of health, health workforce, health care, quality of care, access to care, health expenditure, ageing and long-term care.

The figures and data from the oecd were taken from its public data base (OCDE, 2015). the colombian indicators were taken from official government data from the ministry of health, the national health institute and the national statistics department. the oecd and colombian average data is un-weighted, unless otherwise specified. also, we used data from international institutions such as the world bank, cepal, and the international development bank. some definitions have been taken from the world bank such as, middle-income economies described as those with a gni per capita of more than \$1,045 but less than \$12,746 (world bank, 2015).

Indicators were evaluated according to methodology and scope in order to determine comparability with the indicators presented by the oecd report. we selected indicators including variables such as income and gender, using the free access databases of the OECD, attributing copyright ownership and adding colombian official data. most of the indicators used were from 2011 or the closest available year.

Some of the OECD indicators have no corresponding official data from colombia but in each of



the areas it has been possible to identify some indicators.

### III. RESULTS

#### a) Health Status

OECD and colombia have been showing a tendency to increase the life expectancy, but the methodology used to measure it varies between countries. life expectancy has a tendency to rise in both the OECD countries and colombia; however the methodology varies between countries. Women in all countries had a higher life expectancy than men. women showed better results all the countries.

Life expectancy in colombia has increased from 64.7 (men) and 71.51 (women) in 1985 to 72.1 (men), 78.5 (women) in 2015. (ministerio de salud , 2013.) life expectancy in colombia is 4.2 years less than the average oecd countries. The life expectancy is 6 to 8 years higher among women though the difference between men and women could be reduced by 4 to 5 years by reducing deaths due to violence (ons, 2014). colombia has one of the highest homicide rate in the world 42.5 per 100 000 people in 2009, but is reducing compare with 65.8 in 1999, meanwhile salvador is increasing from 44,9 in 1999 to 62,9 in 2009 (ons, 2014).




Figure 1 : Life expectancy at birth by sex, 2011 (or nearest year)




Figure 2 : Life expectancy Vs health expenditure (USD PPP).

Colombia has important difference in life expectancy between regions being the highest in the capital (75.94 for men and 80.19 for women, and the lowest life expectancies concentrated in eight regions

where life expectancy is less than 70 years: Chocó, Caquetá, Putumayo, Arauca, Casanare, Cauca, Meta and Amazonia) (Ministerio de Salud, 2013). There is no information relating life expectancy to level of education in Colombia.

Colombia has higher infant mortality rate compared with the OECD average (12.8 Vs 4.1), similar to China (12.6) and lower than Brazil (13.9). Many countries have reduced infant mortality in the past decades; Mexico reduced infant mortality from 77 in 1970 to 17 in 2010 and Colombia from 40 to 12.8 in the same period. In some large non-member countries (India, South Africa and Indonesia), infant mortality rates remain above 20 deaths per 1,000 live births (OECD, 2013).




Figure 3 : Infant mortality Rates by country, 2011




Figure 4 : Infant Mortality Rates and Unsatisfied Basic Needs by regions in Colombia 2011

In Colombia, between 2005 and 2011, the main causes of death in the general population were circulatory system diseases, though there has been a decline of this cause (from an adjusted rate of 166.43 to 146.16 deaths per 100,000 inhabitants). Cancer and external causes were the second and third cause of death, accounting for 17.42% (237,930) and 17.33% (236,679) of total deaths respectively from this period (Minsalud, 2013).

Mortality due to circulatory system diseases was 132.2 per 100,000 inhabitants, ischemic disease, 263.7 per 100,000 inhabitants, and cerebrovascular disease was 130.0 per 100,000 inhabitants (PAHO,

2010). This mortality is higher than the OECD average (122), similar to Iceland (133), lower than Hungary (309) and higher than Chile (70).

The average cancer mortality rate across OECD countries was 211 per 100,000 population in 2011, and the most recent data in Colombia, from 2009, was 120 per 100,000 population, lower than Mexico 138.1 and Brazil 2011, however the WHO has been estimated an under-reporting of 24% (PAHO, 2011) which would bring this rate to approximately 149 per 100,000 population.

Suicide rates were 5.0 deaths per 100,000 inhabitants in Colombia (PAHO, 2010), similar to Greece, Turkey, Mexico, Brazil and Italy. In Korea, Hungary, the Russian Federation and Japan, suicide is responsible for more than 20 deaths per 100,000 people.

Fatalities due to car accidents in Colombia were 13.2 deaths per 100,000 lower than Mexico and Chile or Brazil and higher than Sweden, the United Kingdom and Denmark with four deaths or less per 100,000 people (Cendex, 2008).

6.8% of all newborns weighed less than 2,500 grams at birth. The proportion of low-weight births was the lowest in Nordic countries and Estonia, with less than 5% of live births defined as low birth weight. Colombia is showing an increasing tendency in the number of low-weight births, reaching 9.1 in 2010 (INS, 2014).

In almost all OECD countries, a majority of the adult population report their health as good. According to the health survey in Colombia, 72.2% reported their health as good (Rodriguez 2009).

In Colombia diabetes affects 5.2% of the population (Vargas 2011). Diabetes affected an average 6.9% of the OECD population aged 20-79 years, in Mexico, more than 15% of adults have diabetes, but only 5% of adults suffer from diabetes in Belgium, Iceland, Luxembourg, Norway and Sweden.

#### *b) Non-medical Determinants of Health*

In Colombia, current smoking in teenagers between the ages of 11 and 18 (prevalence in the last month) is 9.78%. Smoking among teenagers was 25% in Austria, the Czech Republic, and Hungary and less than 10% in Canada, Iceland, Norway, and the United States. (Cumsille, 2011)

Drunkenness is reported to have been experienced at least twice by more than 40% of 15-year-olds in the Czech Republic, Denmark, Estonia, Finland, Hungary, Slovenia and the United Kingdom. In Colombia, 40% students between the ages of 11 and 18 year-old reported alcohol consumption in the past month, but no data about Drunkenness was found. (Cumsille, 2011)

Overweight (including obesity) rates are approximately 23% for boys and 21% for girls, on average, in OECD countries. In Colombia it is 20.2% for

overweight and 5.2% for obesity for boys and girls (Fonseca, 2011). Daily vegetable consumption was reported to be around 33% in girls and 25% in boys on OECD countries and only 13.5% in Colombia for boys and girls.

In OECD countries, less than 25% of the children reported regular training with moderate-to-vigorous exercise. Austria, Ireland, Spain, and Finland stand out as strong performers with over 30% of children reporting exercising for at least 60 minutes per day over the past week. In Colombia this figure was only 15% (Piñeros, 2010).

Vegetable consumption were less than 15% in India, South Africa, and Brazil. In Colombia 12.8%, similar to Sweden, Iceland and the United States and lower than the average OECD consumption (20%) (Rodriguez, 2009)

Alcohol consumption, as measured by annual sales, stands on average at 9.4 liters per adult per year across OECD countries and Colombia is 6.3 liters per adult per year higher than Costa Rica (3.9), Peru (3.7) y El Salvador (2.6) and lower than Mexico (8.9) (Sojo, 2012).

52.6% of the adult population in the OECD countries are reported as being overweight or obese. In Colombia 34.6% is overweight, including 16.5% obese (Fonseca, 2011). Obesity rates meanwhile vary widely in OECD countries from 4% in Japan and Korea, to over 32% in Mexico and the United States. The average vegetable intake across OECD countries was 64% for men and 73% for women while in Colombia it was only 19.6% per day (Fonseca, 2011).

#### *c) Health workforce*

The rate of doctors per 1 000 inhabitants in Colombia is 2, similar to Korea and lower than Greece with 6.1 doctors per 1 000 inhabitants. Colombia has 13 obstetricians per 100 000 people (Cendex, 2008), lower than all the OECD countries. There are 3 psychiatrists per 100,000 (Rosselli, 2001), compared with 15.6 psychiatrists per 100 000 inhabitants on average across OECD countries, so Colombia has a lower number of mental health professionals.

There were two specialists for every generalist on average across the OECD countries in 2011. The slow growth in, or reduction of, the number of generalists raises concerns about access to primary care. In Colombia there is 1 specialist for every 10 generalists (Cendex, 2008), which would be impressive if it were not for the lack of empowerment of generalists to resolve most primary healthcare issues. The healthcare model continues to be based on specialists with poor implementation of primary health care.

#### *Health care activity*

The number of appointments per person ranged from over 13 in Korea and Japan, and over 11 in Hungary, the Czech Republic and the Slovak



Republic, to three or fewer in Mexico, Sweden, South Africa and Brazil. In Colombia 71% of the population had at least one appointment in 2011, and the average was 1.5 appointments per person (ONS, 2011).

Japan and Korea had over nine hospital beds per 1000 people in 2011 while the average in OECD countries is 5. Colombia has 1.5 beds per 1,000 inhabitants (World Bank, 2012). The hospital stay was on average 4.5 days in OECD countries and in Colombia 3.3 (Ministry of Health, 2005).

In 2011, caesarean section rates were lowest in Nordic countries and the Netherlands, with rates ranging from 15% to 17% of all live births. Caesarean section rates were highest in Mexico and Turkey (over 45%), followed by Chile, Italy, Portugal and Korea (with rates ranging between 35% and 38%). Colombia had a dramatic increase in the number of Caesarean sections with 4.9% in 1998 soaring to 45.7% in 2013 (Rubio, 2014).

In Portugal, the generic market grew from virtually zero in 2000 to 30% in volume in 2011 and in Spain it grew up to 34%. In Colombia generics represented 17% in 2010 and has not shown a significant increase from 14% in 2007. (Econometría, 2011)

#### *d) Quality of Care*

Acute myocardial infarction mortality was low in Denmark (3%) while the highest rate is in Mexico (27%). In Colombia the mortality was 6.7% in 2005 (SILVA, 2006). Colombia reported an IMM rate of 60.9 per 100,000 in women and 93.4 per 100,000 in men showing a small reduction in comparison with 67.1 and 89.1 in 1990 respectively. (Revista Colombiana de Cardiología, 2010)

Across OECD countries, 8.5% of patients died within 30 days in the same hospital in which the initial admission for ischemic stroke occurred. The case-fatality rates were highest in Mexico (19.6%), Slovenia (12.8%) and Turkey (11.8%). Rates were less than 5% in Japan, Korea, Denmark and the United States. In Colombia this rate was 14%. (Zarruk, 2007)

Screening rates for cervical cancer range from 15.5% in Turkey to 85.0% in the United States. Austria, Germany, Sweden, Norway and New Zealand also achieved coverage above 75%. In Colombia 76.5% of the women are screened for cervical cancer. (Piñeros, 2007)

On average, in the OECD countries, 96% of children receive the recommended DTP vaccination and 94% receive measles vaccinations. Rates for DTP and/or measles vaccinations are below 90% only in Austria, Denmark, France, and South Africa. In Colombia the coverage is 93.5% (Minsalud, 2013), but some regions like San Andres have 62% coverage and Caldas 64% coverage, again exposing great differences by zone. The Human Papilloma Virus vaccine had 92% coverage for the second doses (Minsalud, 2013).

#### *e) Access to care*

Two OECD countries do not have universal health coverage. Mexico had 90% of the population covered and in the USA, 53% of the population is covered. Colombia reported 96% coverage in 2013; however this is not necessary equivalent to access to care. (Minsalud, 2014)

The number of doctors per capita varies widely across regions within the same country. A common feature in many countries is the trend for physicians to concentrate in capital cities. In Colombia, in cities with populations less than 20 000 don't reach 0.4 doctors per 10,000 inhabitants while in large cities it is 10 per 10,000. The use of medical services in Colombia is lower among the poor population, at 34%, compared with 47% among the non-poor (Profamilia, 2010).

In Colombia, the risk factors for the omission of cervical cancer screening include no insurance, affiliation to the subsidized healthcare regimen and low educational level. (Piñeros 2007) In breast cancer the risk factors were similar (De Charry, 2008). Income-related inequalities in cervical cancer screening are significant in 15 of the 16 countries in the OECD.

#### *f) Health expenditure and financing*

Colombia had the lowest expenditure compared with the OECD, with \$466 USD Purchasing power parity (PPPs) compared with \$ 3322 USD on average in the OECD, lower than Mexico (\$977) or South Africa (\$942). This expenditure is decreasing in countries such as Greece (-11.1) or Ireland (-6.6) and is increasing in countries such as Chile (9.3) and Colombia (World Bank, 2013).

In Colombia, total healthcare expenditure expressed as a percentage with respect to the GDP represents 6.5% for 2011, with a range from 5.4% in 2004 to 7.0% in 2009. The government's general expenditure as a percentage of GDP represents an average of 4.7%, Private expenditure as a percentage of GDP represents an average of 1.7% and the out-of-pocket expenditure 1.1%, representing 17% of the expenditures (Minsalud, 2014). Healthcare spending accounted for 9.3% of the GDP on average across OECD countries in 2011, compared with 9.4% in 2010.

#### *g) Ageing and long-term care*

On average across OECD countries, 4% of the population was 80 years old and over in 2010. By 2050, the percentage will increase to 10%. In Colombia, this population represented 1.4% of the total population in 2011 and will increase up to 1.5 % in 2020.

In Finland, France, Germany, Greece and Spain, only 35% to 40% of people aged 65 years and over rate their health as good. In Colombia 53.2% of people between 55 to 69 reported their health to be good (Profamilia, 2010).

France, Italy, Switzerland, Spain, Sweden and Norway had the highest prevalence rate of dementia,

with 6.3% to 6.5% of the population aged 60 years. In Colombia 1.8% of 65 years old and 3.4% of 75 years old suffer of dementia.

On average across OECD countries, over 15% of people aged 50 and over provided care for a dependent relative or friend in 2010. Colombia has not comparable data, but 10.1% the population is define as disabled and among them 97% has been taken care by one member of the family (Urquieta, 2008).

#### IV. DISCUSSION

The main achievements of Colombia compared with OECD countries are universal coverage and low out-of-pocket payments. Colombia has some opportunities to show better health indicators due to a younger population, lower rates of diabetes and overweight and a low suicide rate compared with OECD countries. Colombia needs to improve on equality by region, education and income, plus needs to reduce preventable mortality due to violence.

Similar studies were performed in some Latin American countries, such as Chile and Mexico now members of the OECD. In one study from 2013, a comparison was taken from the health indicators in Chile with regard to those countries members of OECD; these studies yielded comparative data with higher indices in diabetes, obesity and suicide in comparison to countries from OECD being 6.9, 17.6 and 12.4 respectively. In addition, a greater out-of-pocket expenditure in health with 4.6% compared with the general average located at 2.86% (Ministerio de Salud Chile, 2013). Studies conducted in Mexico also demonstrate that diseases like diabetes have a higher prevalence, 10.8, compared with countries from the OECD which have 6.5, and with regard to obesity, countries from the OECD have rates of 16.9% while Mexico is 30%. With regard to total health expenditure, the country uses 6.4 % of PIB, well below countries from the OECD with 9.6 (Universidad de Mexico, 2013).

Comparing health expenditure by GDP, countries like Colombia and Mexico are situated at an intermediate level with 500 to 900 dollars per capita annually and Brazil, Costa Rica and Chile in the superior level, with more than one thousand dollars per capita annually (Castro, 2012). Latin American countries with incomes similar to Colombia; like Peru, a country with a per capita income of 6,661.6 (Banco Mundial, 2013-2014), showed the health expenditure per capita for Colombia was a little higher (617.89) than Peru 496.16 according to the Center for National Development Planning of Peru,. With regard to external resources (services offered by international organizations) Colombia received 09% in 2011 while Peru almost doubled that amount with 1.5% (Ceplan, 2014).

Some limitations to be considered in this work may be the result of not utilizing the same tools to measure indicators as well as the absence of data. In addition there is significant under-reporting especially from certain regions of Colombia. Finally, after assembling information regarding the health situation in Colombia, we suggest it is important to advance in quality topics and health service access, in addition to the use of family members as caregivers for the elderly. Last of all, health inequality in the different areas of the country is to be highlighted.

#### REFERENCES RÉFÉRENCES REFERENCIAS

1. Banco Mundial. PIB. (2014, January 1). Retrieved February 28, 2015, From <http://Datos.Bancomundial.Org/Indicador/NY.GDP.PCAP.CD>
2. Castro, C. (2012, July 1). Salud Y Seguridad Social: Un Breve Comparativo De Cinco Países De América Latina. Retrieved February 27, 2015, From <http://Library.Fes.De/Pdf-Files/Bueros/Kolumbien/09229.Pdf>
3. Cendex. (2008). Carga De Enfermedad Colombia 2005: Resultados Alcanzados. Bogotá: Pontificia Universidad Javeriana.
4. Centro Nacional De Planeamiento Estratégico (Ceplan). (2014, January 1). El Perú En Los Indicadores Mundiales. Retrieved February 27, 2015, From [Http://Www.Ceplan.Gob.Pe/Documentos/Peru-Indicadores-Mundiales](http://Www.Ceplan.Gob.Pe/Documentos/Peru-Indicadores-Mundiales)
5. De Charry, L., Carrasquilla, G., & Roca, S. (2008). Equidad En La Detección Del Cáncer De Seno En Colombia. *Revista Salud Pública*, 571-582.
6. Econometria. Diagnóstico De La Situación Actual Del Acceso, Uso Racional Y Calidad De Medicamentos. (2011) Tomado De [Http://Www.Minsalud.Gov.Co/Políticas%20Farmaceuticas/Pol%C3%Adtica%20farmac%C3%A9utica/Documentos%20soporte/Diagnostico%20Situaci%C3%B3n%20Farmac%C3%A9utica%20Nacional%202011.Pdf](http://Www.Minsalud.Gov.Co/Políticas%20Farmaceuticas/Pol%C3%Adtica%20farmac%C3%A9utica/Documentos%20soporte/Diagnostico%20Situaci%C3%B3n%20Farmac%C3%A9utica%20Nacional%202011.Pdf)
7. Fonseca, Z., Heredia, A., Ocampo, P., Forero, Y., Sarmiento, O., Álvarez, M., . . . Rodríguez, M. (2011). Encuesta Nacional De La Situación Nutricional En Colombia 2010 ENSIN. Bogotá: Da Vinci Editores & CÍA.
8. Gurria A. Secretary-General - OECD. Lanzamiento Del Proceso De Adhesión De Colombia A La OCDE. Retrieved March 10, 2015, From [Http://Www.Oecd.Org/About/Secretary-General/Lanzamiento-Del-Proceso-De-Adhesion-De-Colombia-A-La-Ocde.Htm](http://Www.Oecd.Org/About/Secretary-General/Lanzamiento-Del-Proceso-De-Adhesion-De-Colombia-A-La-Ocde.Htm)
9. Instituto Nacional De Salud (INS). Bajo Peso Al Nacer A Término. (2014, June 11). Retrieved March



- 4, 2015, From [Http://Www.Ins.Gov.Co/Lineas-De-Accion/Subdireccion-Vigilancia/Sivigila/Protocolos SIVIGILA/PRO Bajo Peso Al Nacer A Termino.Pdf](http://www.ins.gov.co/Lineas-De-Accion/Subdireccion-Vigilancia/Sivigila/Protocolos/SIVIGILA/PRO_Bajo_Peso_Al_Nacer_A_Termino.Pdf)
10. Kelley, E., & Hurst, J. (2006). Health Care Quality Indicators Project. Retrieved From [Http://Www.Oecd-Ilibrary.Org/Content/Workingpaper/440134737301](http://www.oecd-ilibrary.org/content/workingpaper/440134737301)
11. Ministerio De Salud. (2013) ASIS 24022014.Pdf. (N.D.). Retrieved March 10, 2015, From [Http://Www.Minsalud.Gov.Co/Sites/Rid/Lists/Bibliotecadigital/RIDE/VS/ED/PSP/ASIS%2024022014.Pdf](http://www.minsalud.gov.co/sites/rid/lists/bibliotecadigital/RIDE/VS/ED/PSP/ASIS%2024022014.Pdf)
12. Ministerio De Salud. Política Nacional De Prestación De Servicios. (2005) Tomado De [Http://Www.Minsalud.Gov.Co/Ministerio/Documents/Politica%20Nacional%20de%20Prestaci%C3%B3n%20de%20Servicios%20de%20Salud.Pdf](http://www.minsalud.gov.co/Ministerio/Documents/Politica%20Nacional%20de%20Prestaci%C3%B3n%20de%20Servicios%20de%20Salud.Pdf)
13. Ministerio De Salud De Chile. Panorama De Salud 2013. (2013, January 1). Retrieved March 4, 2015, From [Http://Web.Minsal.Cl/Sites/Default/Files/INFORME OCDE\\_2013\\_21\\_11\\_Final.PDF](http://web.minsal.cl/sites/default/files/INFORME_OCDE_2013_21_11_Final.PDF)
14. Minsalud. (2014). Cifras Financieras Del Sector Salud: Gasto En Salud De Colombia: 2004-2011. Bogotá: Minsalud.
15. Ministerio Hacienda. DECRETO 1192 DE 05-JUNIO-2012.Pdf. (N.D.). Retrieved From [Http://Www.Minhacienda.Gov.Co/Portal/Page/Portal/Homeminhacienda/Elministerio/Normativaminhacienda/2012/DECRETO%201192%20DE%2005-JUNIO-2012.Pdf](http://www.minhacienda.gov.co/Portal/Page/Portal/Homeminhacienda/Elministerio/Normativaminhacienda/2012/DECRETO%201192%20DE%2005-JUNIO-2012.Pdf)
16. OECD. Oede Establece Hoja De Ruta Para Adhesión De Colombia. (N.D.). (2013) Retrieved March 10, 2015, From [Http://Www.Portafolio.Co/Economia/Oede-Establece-Parametros-Ingreso-Colombia](http://www.portafolio.co/economia/Oede-Establece-Parametros-Ingreso-Colombia)
17. OECD Statistics. (N.D.). Retrieved March 10, 2015, From [Http://Stats.Oecd.Org/Index.aspx](http://stats.oecd.org/index.aspx)
18. OECD. (2013). Health At A Glance 2013. OECD Publishing. Retrieved From [Http://Www.Oecd-Ilibrary.Org/Social-Issues-Migration-Health/Health-At-A-Glance-2013\\_Health\\_Glance-2013-En](http://www.oecd-ilibrary.org/social-issues-migration-health/Health-At-A-Glance-2013_Health_Glance-2013-En)
19. ONS. Aspectos Relacionados Con La Frecuencia De Uso De Los Servicios De Salud, Mortalidad Y Discapacidad En Colombia, 2011. Tomado De: [Http://Www.Ins.Gov.Co/Lineas-De-Accion/ONS/Siteassets/Paginas/Publicaciones/Informe-Final%20ONS.Pdf](http://www.ins.gov.co/Lineas-De-Accion/ONS/Siteassets/Paginas/Publicaciones/Informe-Final%20ONS.Pdf)
20. ONS. Violencia Homicida En Colombia. (2014, January 1). Tomado De: [Http://Www.Ins.Gov.Co/Lineas-De-Accion/ONS/Siteassets/Paginas/Publicaciones/Informe4to-ONS-Fe25.Pdf](http://www.ins.gov.co/Lineas-De-Accion/ONS/Siteassets/Paginas/Publicaciones/Informe4to-ONS-Fe25.Pdf)
21. PAHO. (2010). Indicadores Básicos 2010: Situación De Salud En Colombia. Bogotá: Ministerio De La Protección Social.
22. PAHO. (2011) Mortalidad Según Condiciones De Vida. Retrieved March 10, 2015, From [Http://Ww w.Col.Ops-Oms.Org/Sivigila/Mortalidad/Indice.Htm](http://www.col.ops-oms.org/sivigila/mortalidad/indice.htm)
23. Piñeros, M., & Pardo, C. (2010). Actividad Física En Adolescentes De Cinco Ciudades Colombianas: Resultados De La Encuesta Mundial De Salud A Escolares. *Rev. Salud Pública*, 903-914.
24. Piñeros, M., Cendales, R., Murillo, R., Weisner, C., & Tovar, S. (2007). Cobertura De La Citología De Cuello Uterino Y Factores Relacionados En Colombia, 2005. *Revista Salud Pública*, 327-341
25. Profamilia. ENCUESTA NACIONAL DE DEMOGRAFÍA Y SALUD 2010. Tomado De [Http://Www.Pro familia.Org.Co/Encuestas/Profamilia/Profamilia/Index.Php?Option=Com\\_Content&View=Article&Id=62&Itemid=9](http://www.profamilia.org.co/encuestas/profamilia/profamilia/index.php?option=com_content&view=article&id=62&Itemid=9)
26. Revista Colombiana De Cardiología. Guías Colombianas De Cardiología Síndrome Coronario Agudo Con Elevación Del St. (2010). *Revista Colombiana De Cardiología*, 17(0120-5633).
27. Rodríguez, J., Ruíz, F., Peñaloza, E., Eslava, J., Gómez, L., Sánchez, H., . . . Bolivia, Y. (2009). Encuesta Nacional De Salud 2007: Resultados Nacionales. Bogotá: Fundación Cultural Javeriana De Artes Gráficas.
28. Rosselli, D., Otero, A., Heller, D., Calderón, C., Moreno, S., & Pérez, A. (2001). Estimación De La oferta De Médicos Especialistas En Colombia Con El Método De Captura-Recaptura. *Revista Panamericana De Salud Pública*, 393-398.
29. Rubio-Romero, J. A., Fonseca-Pérez, J. E., Molina, S., Buitrago Leal, M., Zuleta, J. J., Ángel-Müller, E., ... Others. (2014). Racionalización Del Uso De La Cesárea En Colombia. Consenso De La Federación Colombiana De Obstetricia Y Ginecología (FECOLSOG) Y La Federación Colombiana De Perinatología (FECOPEN). Bogotá, 2014. *Rev. Colomb. Obstet. Ginecol*, 65(2), 139-151.
30. SILVA, Federico A Et Al. Enfermedad Cerebrovascular En Colombia. *Rev. Col. Cardiol.* [Online]. 2006, Vol.13, N.2 [Cited 2015-03-10], Pp. 85-89 . Available From: <[Http://Www.Scielo.Org.Co/Scielo.Php?Script=Sci\\_Arttext&Pid=S0120-56332006000500008&Lng=En&Nrm=Iso](http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-56332006000500008&lng=en&nrm=iso)>. ISSN0120-5633
31. Sojo, C. (2012). Patrones De Consumo De Alcohol En América Latina. Análisis Comparado De 9 Países. Flacso Costa Rica. Retrieved From [Http://Biblioteca.Lcap.Ac.Cr/BLIVI/COLECCION\\_UNPAN/BOL\\_JUNIO\\_2012\\_51/FLACSO/Carlos\\_Sojo.Pdf](http://biblioteca.lcap.ac.cr/BLIVI/COLECCION_UNPAN/BOL_JUNIO_2012_51/FLACSO/Carlos_Sojo.Pdf)
32. Universidad Nacional Autónoma De México La Salud En Mexico En Perspectiva Comparada. (2013,

- January 1). Retrieved March 3, 2015, From [Http://Biblio.Juridicas.Unam.Mx/Libros/7/3274/5.Pdf](http://Biblio.Juridicas.Unam.Mx/Libros/7/3274/5.Pdf)
33. Urquieta-Salomón, J. E., Figueroa, J. L., & Hernández-Prado, B. (2008). El Gasto En Salud Relacionado Con La Condición De Discapacidad: Un Análisis En Población Pobre De México. *Salud Pública De México*, 50(2), 136–146.
  34. Vargas, H. (2011). Epidemiología De La Diabetes Mellitus. En A. C. Endocrinología, Fascículos De Endocrinología: Fascículos Diabetes (Págs. 22-27). Bogotá: Comité Editorial Fascículo Diabetes.
  35. World Bank. Country And Lending Groups | Data. (N.D.). Retrieved March 10, 2015, From [Http://Data.Worldbank.Org/About/Country-And-Lending-Groups](http://Data.Worldbank.Org/About/Country-And-Lending-Groups)
  36. Zarruk, J. G., Silva, F. A., Camacho López, P., Arenas Borda, W., Restrepo, J., Bernal, O., ... Córdoba, A. (2007). Factors Associated To Mortality Alter 30 Days, In A Group Of Patients With Cerebro-Vascular Ischemic Disease (Stroke). *Acta Medica Colombiana*, 32(1), 2–8.
  37. Cumsille, F., Fagua, J., & Scopetta, O. (2011). Estudio nacional de consumo de sustancias psicoactivas en población escolar. Bogotá: Oficina de las Naciones Unidas contra la Droga y el Delito en Colombia.

#### *Author's Participation*

The Authors Have Been Involved In The Data Collection, Analysis, Writing And Correction Of This Paper.

#### *Conflict Of Interest Statement*

The authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest, or non-financial interest the subject matter or materials discussed in this manuscript.

#### *Funding*

The article analysis has no external funding.

#### *Ethical Consideration*

This article use secondary data and does not imply any kind of intervention with people and according to the helsinki declaration has no risk.

## V. ACKNOWLEDGEMENTS

The authors acknowledge the oecd for their generosity in providing free access to their data base and analysis. special thanks to ian forde and rodrigo moreno for their visit to colombia as part of the OECD health committee.



This page is intentionally left blank



GLOBAL JOURNAL OF MEDICAL RESEARCH: K  
INTERDISCIPLINARY

Volume 15 Issue 2 Version 1.0 Year 2015

Type: Double Blind Peer Reviewed International Research Journal

Publisher: Global Journals Inc. (USA)

Online ISSN: 2249-4618 & Print ISSN: 0975-5888

## Intranasal Antifungal Therapy in Patients with Chronic Illness Associated with Mold and Mycotoxins: An Observational Analysis

By Joseph H. Brewer, Dennis Hooper & Shalini Muralidhar

*University of St. Lukes Hospital, Kansas City, Missouri, United States*

**Abstract-** Exposure to mycotoxin producing mold and mycotoxins can be associated with numerous adverse health consequences. We previously reported that patients with chronic illness frequently had a history of prior exposure to water damaged buildings (WDB) and mold. Additionally, the vast majority of these patients had mycotoxins present in the urine. We have postulated that the mycotoxin producing molds were likely harbored internally in the sinuses of these patients. In the present analysis, patients with chronic illness and a positive urine mycotoxin assay were treated with intranasal antifungal therapy, either amphotericin B (AMB) or itraconazole (ITR). AMB was associated with local (nasal) irritation adverse effects (AE) in 34% of the cases, which resulted in discontinuation. In patients that remained on therapy without AE, we found that 94% improved clinically. Additionally, we found that the urine mycotoxin levels decreased substantially in patients that improved on therapy. Similar findings were seen with ITR, however the number of patients treated was much smaller.

**Keywords:** *toxic mold, mycotoxin, chronic fatigue syndrome, intranasal antifungal therapy.*

**GJMR-K Classification:** *NLMC Code: QV 252*



*Strictly as per the compliance and regulations of:*



# Intranasal Antifungal Therapy in Patients with Chronic Illness Associated with Mold and Mycotoxins: An Observational Analysis

Joseph H. Brewer <sup>α</sup>, Dennis Hooper <sup>σ</sup> & Shalini Muralidhar <sup>ρ</sup>

**Abstract-** Exposure to mycotoxin producing mold and mycotoxins can be associated with numerous adverse health consequences. We previously reported that patients with chronic illness frequently had a history of prior exposure to water damaged buildings (WDB) and mold. Additionally, the vast majority of these patients had mycotoxins present in the urine. We have postulated that the mycotoxin producing molds were likely harbored internally in the sinuses of these patients. In the present analysis, patients with chronic illness and a positive urine mycotoxin assay were treated with intranasal antifungal therapy, either amphotericin B (AMB) or itraconazole (ITR). AMB was associated with local (nasal) irritation adverse effects (AE) in 34% of the cases, which resulted in discontinuation. In patients that remained on therapy without AE, we found that 94% improved clinically. Additionally, we found that the urine mycotoxin levels decreased substantially in patients that improved on therapy. Similar findings were seen with ITR, however the number of patients treated was much smaller.

**Keywords:** toxic mold, mycotoxin, chronic fatigue syndrome, intranasal antifungal therapy.

## I. INTRODUCTION

There has been a growing body of scientific literature indicating that exposure to mycotoxin producing molds and mycotoxins may be hazardous to the health of occupants of WDB (homes, schools and places of business) [1]. Water-damaged environments contain a mixture of biocontaminants produced by both mold and bacteria [1]. Secondary metabolites of molds (e.g. mycotoxins) have been identified in a variety of building materials and respirable airborne particulates, most commonly in WDB [2,3].

Using a sensitive and specific assay developed by RealTime Laboratories (RTL), we recently published a study linking the presence of aflatoxins (AT), ochratoxin A (OT) and/or macrocyclic trichothecenes (MT) to chronic fatigue syndrome (CFS) [4]. A significant number of these chronically ill patients were ill for many years, with average illness duration of more than seven years (range 2–36). Furthermore, over 90% of the patients gave a history of exposure to a WDB, mold or both. Exposure histories often indicated the WDB/ mold

exposure occurred many years prior to the mycotoxin testing and furthermore, many of these patients did not report recent or current exposure to a WDB or moldy environment. Despite the remote history of exposure, these patients remained chronically ill and demonstrated the presence of significantly elevated concentrations of mycotoxins on urine testing. The persistence of illness years after exposure as well as the presence of mycotoxins suggested that there might be internal mold that represented a reservoir for ongoing internal mycotoxin production, either continuous or intermittent.

Recently we described the concept that the nose and sinuses may be the major internal reservoirs where the mold is harbored in biofilm communities [5]. This presence of mold can lead to the generation of mycotoxins internally. Thus, treatments aimed at reduction or elimination of the mold/fungi in the paranasal sinuses could lead to clinical improvement and in these patients. Herein, we present and discuss our observations in chronically ill patients who were treated with intranasal antifungal therapy.

## II. METHODS AND MATERIALS

### a) Patients

All patients discussed herein had previously been diagnosed with CFS, similar to the patient population described in our previous study of mycotoxins in CFS [4]. Additionally, all were positive on the urine mycotoxin assay for at least one of the mycotoxins mentioned above. The age range of the patients reported and female to male ratio was very similar to the patient population previously published, in which the age range was 15 – 72 years and 75% of the patients were females [4].

The rationale for the treatment with intranasal antifungal therapy was outlined in our previous paper regarding the role of naso-sinus colonization with toxic mold [5]. The concepts relating to such therapy were discussed with these patients at the time of a clinic visit. In patients that wanted to proceed with therapy, a prescription was then sent to ASL Pharmacy (see below). The patients were typically seen in follow up within three to six months after initiating therapy. All patients reported herein were seen at least once in follow up after they started therapy.

**Author α:** Plaza Infectious Disease and St. Luke's Hospital, Kansas City, Missouri. e-mail: jbrewer@plazamedicine.com

**Author σ ρ:** RealTime Laboratories, Carrollton, Texas.

e-mails: dhooper@realtimelab.com, smuralidhar@realtimelab.com

Institutional Review Board exemption was granted by Solutions IRB (Protocol #1FEB15-40). This was based on the fact that these patients were treated as part of their clinical management in the medical practice and not deemed to represent human subjects research.

#### b) Treatment

The therapy prescribed consisted of intranasal medications administered via an atomizer device. One agent was used to break up biofilm and the other an antifungal. Prescriptions were sent to ASL Pharmacy, Camarillo, California and then dispensed to the patients by ASL. The agents used to disrupt the biofilm consisted of a combination of ethylenediaminetetraacetic acid (EDTA) and a surfactant (polysorbate 80). Hereafter we will refer to that combination as the chelating agent (CHE). The CHE, which consisted of 2 milliliter (mL) of solution, was always given first, before the antifungal. The intranasal antifungal agents were either AMB or ITR. The AMB consisted of 5 mg in a solution of 3 mL. ITR consisted of 40 mg mixed in a solution of 4 mL. All intranasal applications were delivered via the Nasa Touch atomizer device provided to the patient by ASL Pharmacy. Patients generally administered the atomizer treatments once daily for each agent. The patients were advised to administer the CHE and respective antifungal separately (usually the CHE in the morning and the antifungal in the evening). Patients generally remained on therapy unless they discontinued it due to an AE. As discussed below, seven patients discontinued therapy unrelated to AE. The period of treatment observation ran for 12 months, May 2013 to May 2014.

#### c) Clinical Assessments

At the time of follow up clinic visits, each patient was asked to self-assess their improvement or lack thereof, that had occurred since starting therapy (compared to baseline symptoms before therapy). Improvements were categorized as: partial improvement (25% to 49% decrease in symptoms from baseline), moderate improvement (50% to 74% decrease in symptoms from baseline) or marked improvement (75% to 100% decrease in symptoms from baseline). The most common symptoms present at baseline and those commonly reported to improve on therapy were: fatigue, post-exertion malaise, body aching, headache and cognitive dysfunction. Since most patients had multiple symptoms, they were asked to make a global assessment as to whether they were overall improved from baseline and the degree (percent) of improvement. For purposes of the results reported in the Tables, the improvements (partial, moderate or marked) were grouped together. Thus, "improvement" represented at least a 25% or greater reduction in symptoms compared to baseline. Relapse was defined as recurrence of baseline symptoms after initial improvement.

At follow up, patients were also asked about AE that had occurred with the intranasal treatments. AE

tended to be either local or systemic. Common local AE consisted of irritation symptoms in the nose and sinuses, to include: burning, congestion, nosebleeds, stuffiness, rhinorrhea and nasal/sinus pain. Systemic AE were always an exacerbation of baseline symptoms: fatigue (most common), headache, body aching and cognitive dysfunction. These were thought to be "die off" reactions (see below)

#### d) Mycotoxin testing

The urine mycotoxin testing of specimens were performed at RealTime Laboratories. The details of the assay have been previously described [4].

### III. RESULTS

During the 12-month period of observation, 151 patients initiated therapy with CHE and AMB. An additional 14 were treated with CHE and ITR. The clinical results for each group are summarized in Tables 1 and 2.

Table 1: Patients Treated with Amphotericin B (AMB)

Group	Number	%
AMB Total Patients	151	100
AMB Clinical Response: Improved*	88	58
AMB Local AE Resulting in Discontinuation**	52	34
AMB Systemic AE Total (with or without Local AE)***	19****	13
AMB Continued Therapy & Improved	88	94

\*Improvement defined in Methods section, \*\*Local AE defined in Methods section, \*\*\*Systemic AE defined in Methods section, \*\*\*\*5 patients discontinued therapy due to systemic AE

Table 2: Patients Treated with Itraconazole (ITR)

Group	Number	%
ITR Total Patients	14	100
ITR Clinical Response: Improved*	8	57
ITR Local AE Resulting in Discontinuation**	1	7
ITR Systemic AE Total (with or without Local AE)***	3****	21
ITR Continued Therapy & Improved	8	80

\*Improvement defined in Methods section, \*\*Local AE defined in Methods section, \*\*\*Systemic AE defined in Methods section, \*\*\*\*all 3 patients discontinued therapy due to systemic AE



A subset of patients (n = 20) had repeat mycotoxin testing performed after several months on therapy. Of the 20 patients, 16 had been on AMB and 4 on ITR. Results of the repeat testing and clinical responses are summarized in Table 3. These patients continued on therapy, generally for greater than 6 months.

Additionally, seven patients, that had clinically improved, discontinued therapy (six from the AMB group and one on ITR). The most common reason given for discontinuation was that the patient felt as though they were probably “cured.” These patients had repeat mycotoxin levels done while on therapy and another level after therapy had been discontinued. The data with regard to relapses and results of repeat mycotoxin levels

after discontinuation of their treatments are seen in Table 4. In these patients, they had been on therapy at least 6 months when they discontinued the intranasal medication.

In summarizing the results from our patient observations, treatments with both AMB and ITR resulted in clinical improvement (reduction in symptoms).

In patients that used the AMB and remained on therapy without AE, 88 of 94 (94%) improved. Within this group, 26 of 88 patients (30%) graded their improvement as “marked” (defined above). We also found that AMB led to a decrease in the levels of mycotoxins in the urine assay.

**Table 3:** Subgroup of Patients on Therapy with Repeat Mycotoxin Assays

Rx	Imp	%	AT dec	%	OT dec	%	MT dec	%	Total
AMB	14/16	88	4/4*	100	14/14*	100	11/15	73	16
ITR	3/4	75	1/1	100	3/4	75	3/4	75	4

*Rx: Treatment, Imp: improved, AT dec: aflatoxin level decreased, OT dec: ochratoxin A level decreased, MT dec: macrocyclic trichothecene level decreased, AMB: amphotericin B, ITR: itraconazole, \*decreased down to a level of zero (AT 4/4, OT 14/14)*

**Table 4:** Subgroup of Patients that Discontinued Therapy (after Improvement)

Rx	Imp	%	Relap	%	AT inc	%	OT inc	%	MT inc	%
AMB	6	100	5/6	83	n/a	n/a	3/4	75	4/4	100
ITR	1	100	1/1	100	n/a	n/a	1/1	100	1/1	100

*Rx: Treatment, I: improved, Relap: clinical relapse after discontinuation, AT inc: aflatoxin level increased compared to level obtained on treatment, OT inc: ochratoxin A level increased compared to level obtained on treatment, MT inc: macrocyclic trichothecene level increased compared to level obtained on treatment, AMB: amphotericin B, ITR: itraconazole, n/a: not applicable*

In the subset of patients on AMB (n = 16) that continued on therapy (generally at least 6 months) and had at least one repeat urine mycotoxin assay done, these repeat assays showed rather substantial and consistent decreases in the urine mycotoxin levels from baseline levels. AT (n = 4) and OT (n = 14) levels decreased in all cases tested and in all of these patients the levels dropped to zero. MT levels (n = 16) declined in 73%, albeit none dropped to zero. Several MT levels dropped rather dramatically, however, with levels as low as 0.01 ppb (data not shown).

Local AE in the nose and sinuses that resulted in discontinuation of therapy were common, seen in 34% of the patients on AMB. As noted above, systemic AE were not new symptoms, rather consisted of exacerbations of the patient’s baseline symptoms. We felt these were most likely fungal “die off” reactions. These were frequently temporary, often lasting less than 3 to 4 weeks. However, in five AMB patients the systemic AE resulted in discontinuation. These systemic AE were not common, only seen in 13% of the AMB cases, albeit we suspect that these AE may have been under reported, given that a fairly high percentage of patients stopped therapy early due to local AE. AE that

are reported with AMB, when administered intravenously, such as chilling, were not seen [6]. We did not see any systemic AE that were considered to be directly due to AMB [6].

ITR was quite effective, as well (albeit the numbers are much smaller). We noted clinical improvement in 80% of these cases. We also saw a decrease in mycotoxin levels in ITR patients that had improved. Local AE were uncommon (less common than those seen with AMB). Systemic AE (presumably “die off”) were seen with ITR but were uncommon.

We were also able to look at relapses in patients that had improved and elected to discontinue therapy. In seven patients that discontinued therapy (after improvement), six relapsed clinically (five on AMB and one that had received ITR). Most of these patients discontinued therapy around 6 months into the course of therapy. Furthermore, when mycotoxin levels were repeated after discontinuation of therapy (and relapse), the levels increased as compared to levels when on therapy (Table 4). OT levels increased after the patients stopped therapy in three of four cases. MT levels increased off therapy in four of four cases. When these patients resumed therapy (after discontinuation and

relapse) their symptoms consistently improved again (data not shown).

#### IV. DISCUSSION

Exposure to WDB, in particular, toxic mold, has been associated with numerous adverse health consequences [1,4]. We have studied patients with chronic illness, with the prototype being CFS. We found the chronic illness was highly associated with exposure to WDB/mold in the past and the ongoing presence of mycotoxins, detected with a sensitive and specific urine assay [4]. As we analyzed these patients, it became apparent that many of the patients with chronic illness and the presence of mycotoxins could trace their illness to past exposure but not recent or present exposure. We postulated that these patients may have harbored internal mycotoxin producing mold species and that such mold was likely in the sinuses, embedded in biofilm. A review of the literature and patient data supporting this idea was previously published [5]. Indeed, if these patients harbored mycotoxin producing molds/fungi in the sinuses, it seemed intuitive that therapies directed at reduction or elimination of this mold biofilm, could potentially lead to clinical improvements. Ponikau et al had previously found that fungi were very commonly found in the sinuses of chronic rhinosinusitis (CRS) cases [7]. This same group also showed that intranasal therapy with AMB had resulted in improvement in several clinical parameters in CRS patients [7]. Furthermore, AMB has been shown to be effective in fungal biofilm models [8]. Based on these types of data, we elected to offer treatment (intranasal AMB) to patients that were chronically ill (CFS) and had tested positive for mycotoxins.

We analyzed and report on 151 patients that initiated therapy with CHE and AMB, each administered once daily. Unfortunately, local AE in the nose and sinuses that resulted in discontinuation of therapy were common, seen in 34% of the AMB patients. These local AE were likely due to the irritation characteristics of AMB [6]. In patients that had minimal, if any local AE, the results were striking. We found that 94% of patients that continued on therapy (usually 6 months or longer) improved clinically. This was not particularly surprising given the prior published experiences with intranasal AMB in CRS cases, which frequently resulted in improvements in various clinical parameters (symptoms, endoscopic findings and computed tomography imaging results) [7]. Additionally, in our patients on AMB that improved and had repeat urine mycotoxin testing, we demonstrated substantial decreases in the urine mycotoxin levels from baseline levels. We have previously noted that repeat urine mycotoxin levels in patients that were not on any type of therapy did not significantly change from baseline levels (unpublished observations). The decreases in mycotoxin levels in the

patients on intranasal AMB showed a very good correlation with clinical improvements. Systemic AE (presumably “die off” reactions) were not common but may have been under reported, as noted above. We suspect, in the patients reported herein, that the systemic “die off” reactions were due to enhanced mycotoxin release when the therapy was initiated, as a direct result of the AMB interacting with the mold/fungi in the sinuses. In an in vitro model, Reeves et al demonstrated increased synthesis and release of gliotoxin from *Aspergillus fumigatus* upon exposure to amphotericin B [9]. Other than the local AE and “die off” reactions, AE directly attributable to AMB were not seen. Ponikau et al tested the sera of 3 patients for AMB in CRS patients treated with AMB and found no detectable drug [7]. Thus, it appears that AMB has no systemic absorption from the nose or sinuses.

We also studied intranasal ITR. Initially, we were concerned that it may be less effective due to the reports of poor biofilm activity [8]. However, we tried ITR as an alternative therapy in a small group of patients (n = 14). Despite the in vitro data regarding limited biofilm activity, when given along with the CHE, ITR was quite effective, as well (albeit the numbers were much smaller). Since ITR is orally bioavailable, it is potentially absorbed from the nose and sinuses in the setting of intranasal therapy. Albeit relatively small doses of ITR are used with intranasal therapy, there is the possibility of AE from the drug directly since we assume it could be absorbed systemically from the sinuses.

Patients that had improved and discontinued therapy at approximately 6 months generally relapsed (six of seven patients). Furthermore, compared to the decreases in urine mycotoxin levels while on therapy, these levels increased after the patients had stopped their intranasal therapy. Thus, the duration of therapy remains a major question. Whether longer courses of therapy will be efficacious resulting in long term remissions remains unclear. It may be that some patients may need “maintenance” therapy to prevent relapses.

As stated earlier, the goal of intranasal antifungal therapy is reduction or elimination of the mycotoxin producing molds in the sinuses. From the data shown here, it appears that the mold levels in the sinuses can be reduced with intranasal therapy. It is unknown whether the mold can be eradicated.

#### V. CONCLUSIONS

Despite the local AE (particularly AMB) and relapses when therapy was discontinued, the success rate with intranasal therapy was very encouraging. One major obstacle was the intolerance with AMB secondary to local AE. This analysis of intranasal antifungal therapy directed at mycotoxin producing fungi and biofilm in the sinuses, offers a very promising therapy alternative for patients with chronic illness associated with mycotoxins

## VI. FUTURE DIRECTIONS

There remain a number of unanswered questions with regard to intranasal antifungal therapy in these types of patients. The agent of choice, proper dose, frequency of dosing, most effective way to administer the therapy and duration of therapy have not been fully elucidated. In view of the frequent local AE with AMB, other antifungal agents need to be addressed. Certainly, ITR is one available option, however, the potential for systemic absorption is a concern, as noted above. Another option is intranasal nystatin. Although used for decades as a topical agent for yeast infections, nystatin actually has good in vitro activity for molds [10]. Since nystatin is a polyene antifungal agent (similar to AMB), it would be predicated to have similar effects. Hopefully, there may be less local AE due to nasal irritation. Additionally, nystatin is not systemically absorbed and has a long track record of clinical safety. Intranasal nystatin was not available when this study was done. It may be a potential option to pursue.

There is also interest in alternative agents to break up the biofilm. In that regard, mupirocin has been studied in CRS patients and has been an effective therapy [11]. Additionally, mupirocin appears to be active against biofilm [12]. It may represent an interesting agent to address for these types of patients in the future.

## REFERENCES RÉFÉRENCES REFERENCIAS

1. Thrasher JD, Crawley S. The biocontaminants and complexity of damp indoor spaces: more than what meets the eyes. *Toxicol Ind Health* 2009; 25:583–615.
2. Täubel M, Sulyok M, Vishwanath V, Bloom E, Turunen M, Järvi K, Kauhanen E, Krska R, Hyvärinen A, Larsson L, Nevalainen A. Co-occurrence of toxic bacterial and fungal secondary metabolites in moisture-damaged indoor environments. *Indoor Air* 2011; doi:10.1111/j.1600-0668.2011.00721.x.
3. Brasel D, Douglas R, Wilson SC, Straus DC. Detection of airborne *Stachybotrys chartarum* macrocyclic trichothecene mycotoxins on particulates smaller than conidia. *Appl Environ Microbiol* 2005; 71:114–22.
4. Brewer JH, Thrasher JD, Straus DC, Madison RA, Hooper D. Detection of mycotoxins in patients with chronic fatigue syndrome. *Toxins* 2013; 5: 605–17.
5. Brewer JH, Thrasher JD, Hooper D. Chronic illness associated with mold and mycotoxins: is naso-sinus fungal biofilm the culprit? *Toxins* 2014; 6:66-80.
6. Bristol-Myers Squibb. Fungizone Product Monograph; Bristol-Myers Squibb Canada: Montreal, Canada, 2009
7. Ponikau JU, Sherris DA, Weaver A, Kita H. Treatment of chronic rhinosinusitis with intranasal amphotericin B: A randomized, placebo-controlled, double-blind pilot trial. *J. Allergy Clin Immunol* 2005; 115:125–31.
8. Mowat E, Butcher J, Lang S, Williams C, Ramage G. Development of a simple model for studying the effects of antifungal agents on multicellular communities of *Aspergillus fumigatus*. *J Med Microbiol* 2007; 56:1205–12.
9. Reeves EP, Murphy T, Daly P, Kavanagh, K. Amphotericin B enhances the synthesis and release of the immunosuppressive agent gliotoxin from the pulmonary pathogen *Aspergillus fumigatus*. *J Med Microbiol*. 2004; 53:719-25.
10. Oakley KL, Moore CB, Denning DW. Comparison of in vitro activity of liposomal nystatin against *Aspergillus* species with those of Nystatin, Amphotericin B (AB) Deoxycholate, AB Colloidal Dispersion, Liposomal AB, AB Lipid Complex and Itraconazole. *Antimicrob Agents Chemother*. 1999; 43:1264-66.
11. Uren B, Psaltis A, Wormold PJ. Nasal lavage with mupirocin for the treatment of surgically recalcitrant chronic rhinosinusitis. *Laryngoscope* 2008; 118:1677–80.
12. Le T, Psaltis A, Tan LW, Wormold PJ. The efficacy of topical biofilm agents in a sheep model of rhinosinusitis. *Am J Rhinol*. 2008; 22:560-67.



This page is intentionally left blank



GLOBAL JOURNAL OF MEDICAL RESEARCH: K  
INTERDISCIPLINARY

Volume 15 Issue 2 Version 1.0 Year 2015

Type: Double Blind Peer Reviewed International Research Journal

Publisher: Global Journals Inc. (USA)

Online ISSN: 2249-4618 & Print ISSN: 0975-5888

## Data and Edits in Healthcare Information Management

By Sajeesh Kumar

*University of Tennessee Health Science Center, United States*

**Abstract-** This study determine which job function causes or creates a large number of Edit/ Data Overwrites within health care. The study is based on data extracted from the Monthly Reports reported by the Team staff. Out of the 2736 Potential Identity Changes, 115 actually resulted in a CE. The number of CEs created by each job title ranged from 1% by Employee Health Clerk to 28% by Eligibility Clerk. Out of the 115 CEs created, a total of 32 were created by the Eligibility Clerks. The next highest job title was the Enrollment/Registration Clerks with 21 CEs created. Of the 4% of CEs reported, Eligibility Clerks created 28% of those CEs and Enrollment/Registration Clerks created 18% of CEs reported during this time period. The findings provide insight to the staff as well as other managers for the users who need additional training or realignment in the workflow. Further work is required to expand and identify factors contributing to incidents causing CEs.

**Keywords:** *data; edits, health informatics.*

**GJMR-K Classification:** *NLMC Code: QT 180*



*Strictly as per the compliance and regulations of:*





# Data and Edits in Healthcare Information Management

Sajeesh Kumar

**Abstract-** This study determine which job function causes or creates a large number of Edit/ Data Overwrites within health care. The study is based on data extracted from the Monthly Reports reported by the Team staff. Out of the 2736 Potential Identity Changes, 115 actually resulted in a CE. The number of CEs created by each job title ranged from 1% by Employee Health Clerk to 28% by Eligibility Clerk. Out of the 115 CEs created, a total of 32 were created by the Eligibility Clerks. The next highest job title was the Enrollment/Registration Clerks with 21 CEs created. Of the 4% of CEs reported, Eligibility Clerks created 28% of those CEs and Enrollment/Registration Clerks created 18% of CEs reported during this time period. The findings provide insight to the staff as well as other managers for the users who need additional training or realignment in the workflow. Further work is required to expand and identify factors contributing to incidents causing CEs.

**Keywords:** data; edits, health informatics.

## I. DATA AND EDITS IN HEALTHCARE INFORMATION MANAGEMENT

There has been a significant increase in the number of occurrences of catastrophic edits to patient identity traits. Catastrophic Edit (CE) are changes to a patient's electronic health record that result in the record being changed to that of another patient, caused by, but not limited to, edits to patient identity data (such as name, Social Security Number (SSN), date of birth, gender) and/or erroneous merging of two or more distinct patient records into a single record.

While monitoring the changes, it has been discovered a recurring issue of catastrophic edits to patient identity traits. These edits are often a result of an inappropriately editing of an existing record through mis-selection or error. These errors can affect administrative, clinical, and billing processes as well as affect patient care causing a significant patient safety risk.

The purpose of this study is to investigate the role (job title) of the originator of the Catastrophic Edits/Data Overwrites to identify the correlation between the role and the number of Catastrophic Edits. The objective of this study is to determine which job function causes or creates a large number of Catastrophic Edits/Data Overwrites.

*Author: PhD, Department of Health Informatics & Information Management, University of Tennessee Health Science Center, 920 Madison Avenue Suite 518, Memphis, Tennessee 38163, USA.  
e-mail: skumar10@uthsc.edu*

## II. BACKGROUND

There are several studies and researches conducted that focuses on the patient safety incident involving human computer related incidents. Magrabi, Ong, Runciman, & Coiera's (2010) conducts a descriptive analysis to examine computer related patient incidents across one Australian state. Ash, Berg & Coiera, 2003 draws on a series of qualitative research studies in the US, the Netherlands and Australia with ethnography observation in healthcare setting and semi-structured interviews with health professionals.

Magrabi, Ong, Runciman, & Coiera (2010) searched 42616 patient safety events incident reported 2003 to 2005 by public hospital clinician to the Advanced Incident Management System. They examined 123 incidents that were computer related incident. Of the 123 incidents retrieved, four duplicates and eight incidents that did not relate to patient safety were removed, leaving 111 incidents. Of the 111 incidents, eight were described as an improvement in patient safety due to Information Technology (IT) and four were unresolvable, leaving 99 incidents. Information input issues accounted for the largest category with 31% of the incidents. These issues included were related incorrect human data entry such as incorrect selection of patient and typographical errors. Information output data accounted for 20% of incidents, which included problems with human-computer interaction such as error in interpreting, printed information due to poor quality or data retrieval errors (Magrabi, Ong, Runciman, & Coiera, 2010).

Ash, Berg and Coiera (2003) discussed errors in the process of entering and retrieving information in or from the system based on ethnographic observations and semi-structured interviews with healthcare professionals. They discussed in detail the problem of a human-computer interface that is not suitable for a highly interruptive use context. By health care professional often being interrupted by patients, telephones and other colleagues, the mismatch between interface and use context often resulted in a juxtaposition error. A juxtaposition error is an error caused when something is close to something else on the screen and the wrong option is too easily clicked in error (Ash, Berg and Coiera, 2003). The authors found there were instances of patient confusion when orders were entered for the wrong patient. They also found that





overly structure data entry led to a loss of cognitive focus. The use of many screens or need to switch between screens results in error.

### III. METHODS

This study examined Catastrophic Edits (CEs) reported by team staff between November 2011 through December 2012. Due to privacy and security policies, the sites and CEs have been de-identified. The role or functional job title of the medical center staff who created the CE options consists of the following job titles: Administrator of the Day (AOD), Clinic Clerk, Clinical (Medical/Surgical) Staff, Eligibility Clerk, Employee Health Clerk, Enrollment/Registration Clerk, Health Eligibility Center (HEC) Staff, Point of Contact (POC), Personnel/Human Resources (HR) Clerk, Privacy Officer, Supervisors, Ward Clerk and Other. The options for how the CE occurred include: Manual, Primary View Updates, Catastrophic Merge, Upload, and unknown, Mismatch/Auto Link.

The data collected from the Monthly CE Reports was compiled using Microsoft Excel. The data was extracted and entered in separate MS Excel worksheets. The data extracted was entered in MS Excel worksheets and categorized by titles of the originator, sites, and how the CE occurred. The number of CEs created and the job title of the creator of the CE were calculated and a bar graph was formulated to identify the actual number of CEs created by each job title. The number of CEs were calculated and a bar graph was formulated to identify the number of CEs. The number potential CEs calculated against the number of actual CEs each month was charted and a bar graph was formulated to compare the potential CEs vs. the actual CEs.

### IV. RESULTS

From November 2011 to December 2012, a total of 2736 Potential Identity Changes occurred. Out

of the 2736 Potential Identity Changes, 115 actually resulted in a CE (Table 2). Table 3 shows the job title of the CE originator in ascending order by the number of CEs created. The number of CEs created by each job title ranged from 1% by Employee Health Clerk to 28% by Eligibility Clerk. Out of the 115 CEs created, a total of 32 were created by the Eligibility Clerks. The next highest jobtitle was the Enrollment/Registration Clerks with 21 CEs created. The MPI POCs and the other job title ranked close with MPI POCs creating 15 CEs and Other creating 16 CEs. The Employee Health Clerks created the lowest number of CEs with 1 CE created followed by the AOD with 2 CEs and Regional Office Staff with 3 CEs. There is a significant difference between the job titles which created the highest number of CEs created compared to the job title which lowest number of CEs.

*Table 2 :* Total Potential ID Change and Edits

	Total Potential ID Changes	Total Catastrophic Edits
	80	10
	87	8
	90	9
	82	8
	92	4
	103	12
	100	6
	359	8
	344	13
	352	8
	715	4
	158	5
	79	17
	95	3
<b>Total</b>	<b>2736</b>	<b>115</b>

*Table 3 :* Job Title of Edits Originators

TITLE OF CE ORIGINATOR	CEs Created	% of CEs Created
Admin Officer of the Day (AOD)	2	2%
Clinic Clerk	8	7%
Clinical (Medical/Surgical) Staff	4	3%
Eligibility Clerk	32	28%
Employee Health Clerk	1	1%
Enrollment/Registration Clerk	21	18%
Health Staff	6	5%
MPI	15	13%
Other	16	14%
Supervisor	7	6%
Regional Office Staff	3	3%
<b>Total</b>	<b>115</b>	

## V. DISCUSSION

In this study various tools were used to examine the role or functional job title of the medical center staff that created the CE on the MPI. The findings reveal that out of the number Potential Identity Changes, 4% actually resulted in a CE, which is considered relatively high compared to the medical staff's goal of creating less than 1% of CEs. This study found that the job titles with the highest occurrence of CEs are Eligibility Clerks and Enrollment/Registration Clerks.

There were several limitations to this study. These findings may be less applicable to other health care institutions or users that edit data within records. Another limitation was in cases where the job title of the CE was undetermined or unknown, the CE was documented and counted in the "Other" section for this study. This may have caused underrepresentation of the job title of the user who created the CE. Lastly, the Catastrophic Edit report used to examine the CEs that have occurred may contain errors or inaccuracies in documentation.

## VI. CONCLUSION

Of the 4% of CEs reported, Eligibility Clerks created 28% of those CEs and Enrollment/Registration Clerks created 18% of CEs reported during this time period. Eligibility Clerks and Enrollment/Registration clerks work in a high traffic multifunctional work environment that results in errors caused by mis-clicking, interruptions, entering and retrieval of wrong patient. According to Magrabi, Ong, Runciman & Coiera, most information input problems were associated incorrect data entry such as incorrect selection of the patient name, data entry in incorrect fields and typographical errors. Factors reported included lack of training, failure to carry out a duty, high cognitive workload and effects of multitasking (2010).

The findings of this study produced useful information about the users to which yield to further research with identifying various causes of CEs. Since this study did not evaluate the actual causes of the CEs, further work is required to expand and identify factors contributing to incidents causing CEs.

## REFERENCES RÉFÉRENCES REFERENCIAS

1. Adelman, J., Kalkut, G., Schechter, C.B., Weiss, J. M., Berger, M. A., Reiddman, S. H., Southern, W. N. (2012). Understanding and preventing wrong patient electronic orders: a randomized controlled trial. Journal of the American Medical Informatics Association. doi 10.1136/amiajnl-2012-001055.
2. Ash, J., Berg, M., & Coiera, E. 2003. Some Unintended Consequences of Information Technology in Health Care: The Nature of Patient Care Information System-related Errors. Journal of the American Medical Informatics Association 11, 2. doi:10.1197/jamia.M1471.
3. Department of Veterans Affairs (2009). Repair of Catastrophic Edits to Patient Identity. Veteran Health Administration (VHA) Handbook 1907.05. Retrieved from: [http://www1.va.gov/vhapublications/ViewPublication.asp?pub\\_ID=2053](http://www1.va.gov/vhapublications/ViewPublication.asp?pub_ID=2053)
4. Department of Veterans Affairs (2009). Data Entry Requirement for Administration Data. VHA Directive 2009-021. Retrieved from [http://www.va.gov/vhapublications/ViewPublication.asp?pub\\_ID=2012](http://www.va.gov/vhapublications/ViewPublication.asp?pub_ID=2012)
5. Magrabi, F., Ong, M., Runciman, W., & Coiera, E. (2010). An analysis of computer related patient safety incidents to inform the development of a classification. Journal of the American Medical Informatics Association. 17, 663-667 doi:10.1136/jamia.2009.002444.

Table 1: Edits Reports

VISN	HOW CE OCCURRED (Manual, etc.)	TITLE OF CE ORIGINATOR
F	Manual	Admin Officer of the Day (AOD)
F	Manual	Admin Officer of the Day (AOD)
H	Manual	Clinic Clerk
H	Manual	Clinic Clerk
I	Manual	Clinic Clerk
J	Manual	Clinic Clerk
J	Manual	Clinic Clerk
L	Manual	Clinic Clerk
L	Manual	Clinic Clerk
U	Manual	Clinic Clerk
G	Manual	Clinical (Medical/Surgical) Staff *
K	Manual	Clinical (Medical/Surgical) Staff *
U	Manual	Clinical (Medical/Surgical) Staff *
V	Manual	Clinical (Medical/Surgical) Staff *
A	Manual	Eligibility Clerk

A	Manual	Eligibility Clerk
A	Manual	Eligibility Clerk
A	Manual	Eligibility Clerk
D	Manual	Eligibility Clerk
F	Manual	Eligibility Clerk
F	Manual	Eligibility Clerk
G	Manual	Eligibility Clerk
G	Manual	Eligibility Clerk
G	Manual	Eligibility Clerk
G	Manual	Eligibility Clerk
H	Manual	Eligibility Clerk
H	Manual	Eligibility Clerk
I	Manual	Eligibility Clerk
I	Manual	Eligibility Clerk
I	Manual/Mismatch	Eligibility Clerk
K	Manual	Eligibility Clerk
P	Manual	Eligibility Clerk
P	Manual	Eligibility Clerk
P	Manual	Eligibility Clerk
P	Manual	Eligibility Clerk
Q	Manual	Eligibility Clerk
Q	Manual	Eligibility Clerk
R	Manual	Eligibility Clerk
R	Manual/Mismatch	Eligibility Clerk
R	Manual	Eligibility Clerk
S	Manual	Eligibility Clerk
T	Manual	Eligibility Clerk
T	Manual	Eligibility Clerk
T	Manual	Eligibility Clerk
U	Manual	Eligibility Clerk
V	Manual	Eligibility Clerk
T	Manual	Employee Health Clerk
C	Manual	Enrollment/Registration Clerk
C	Manual	Enrollment/Registration Clerk
D	Manual	Enrollment/Registration Clerk
D	Manual	Enrollment/Registration Clerk
F	Manual	Enrollment/Registration Clerk
F	Manual	Enrollment/Registration Clerk
G	Manual	Enrollment/Registration Clerk
H	Manual	Enrollment/Registration Clerk
H	Manual	Enrollment/Registration Clerk
H	Manual	Enrollment/Registration Clerk
H	Manual	Enrollment/Registration Clerk
H	Upload	Enrollment/Registration Clerk
I	Manual	Enrollment/Registration Clerk
J	Manual	Enrollment/Registration Clerk
L	Manual	Enrollment/Registration Clerk
O	Manual	Enrollment/Registration Clerk
P	Manual	Enrollment/Registration Clerk
T	Manual	Enrollment/Registration Clerk
U	Manual	Enrollment/Registration Clerk
W	Manual	Enrollment/Registration Clerk
R	Manual	Enrollment/Registration Clerk (DoD)
G	Manual	HEC Staff
G	Manual	HEC Staff
G	Manual	HEC Staff
G	Manual	HEC Staff
G	Manual	HEC Staff
G	Manual	HEC Staff

C	Manual	MPI POC
C	Manual	MPI POC
D	Manual	MPI POC
G	Manual	MPI POC
G	Manual	MPI POC
J	Manual	MPI POC
K	Catastrophic Merge	MPI POC
K	Manual	MPI POC
P	Catastrophic Merge	MPI POC
R	Manual	MPI POC
R	Manual	MPI POC
T	Manual	MPI POC
T	Manual	MPI POC
T	Manual	MPI POC
W	Manual	MPI POC
A	Manual	Other *
D	Manual	Other *
G	Mismatch/Auto-Link	Other *
I	Manual	Other *
P	Manual	Other *
P	Upload	Other *
P	Upload	Other *
P	Upload	Other *
P	Upload	Other *
P	Upload	Other *
P	Upload	Other *
P	Upload	Other *
P	Upload	Other *
P	Upload	Other *
U	Manual	Other *
A	Manual	Supervisor
G	Manual	Supervisor
K	Manual/Catastrophic Merge	Supervisor
T	Manual	Supervisor
U	Manual	Supervisor
W	Manual	Supervisor
W	Manual	Supervisor
J	Manual	Regional Office Staff
T	Manual	Regional Office Staff
W	Manual	Regional Office Staff

# GLOBAL JOURNALS INC. (US) GUIDELINES HANDBOOK 2015

---

[WWW.GLOBALJOURNALS.ORG](http://WWW.GLOBALJOURNALS.ORG)

## FELLOWS

### FELLOW OF ASSOCIATION OF RESEARCH SOCIETY IN MEDICAL (FARSM)

Global Journals Incorporate (USA) is accredited by Open Association of Research Society (OARS), U.S.A and in turn, awards “FARSM” title to individuals. The 'FARSM' title is accorded to a selected professional after the approval of the Editor-in-Chief/Editorial Board Members/Dean.



- The “FARSM” is a dignified title which is accorded to a person’s name viz. Dr. John E. Hall, Ph.D., FARSS or William Walldroff, M.S., FARSM.

FARSM accrediting is an honor. It authenticates your research activities. After recognition as FARSM, you can add 'FARSM' title with your name as you use this recognition as additional suffix to your status. This will definitely enhance and add more value and repute to your name. You may use it on your professional Counseling Materials such as CV, Resume, and Visiting Card etc.

*The following benefits can be availed by you only for next three years from the date of certification:*



FARSM designated members are entitled to avail a 40% discount while publishing their research papers (of a single author) with Global Journals Incorporation (USA), if the same is accepted by Editorial Board/Peer Reviewers. If you are a main author or co-author in case of multiple authors, you will be entitled to avail discount of 10%.

Once FARSM title is accorded, the Fellow is authorized to organize a symposium/seminar/conference on behalf of Global Journal Incorporation (USA). The Fellow can also participate in conference/seminar/symposium organized by another institution as representative of Global Journal. In both the cases, it is mandatory for him to discuss with us and obtain our consent.



You may join as member of the Editorial Board of Global Journals Incorporation (USA) after successful completion of three years as Fellow and as Peer Reviewer. In addition, it is also desirable that you should organize seminar/symposium/conference at least once.

We shall provide you intimation regarding launching of e-version of journal of your stream time to time. This may be utilized in your library for the enrichment of knowledge of your students as well as it can also be helpful for the concerned faculty members.








The FARSM can go through standards of OARS. You can also play vital role if you have any suggestions so that proper amendment can take place to improve the same for the benefit of entire research community.

As FARSM, you will be given a renowned, secure and free professional email address with 100 GB of space e.g. [johnhall@globaljournals.org](mailto:johnhall@globaljournals.org). This will include Webmail, Spam Assassin, Email Forwarders, Auto-Responders, Email Delivery Route tracing, etc.



The FARSM will be eligible for a free application of standardization of their researches. Standardization of research will be subject to acceptability within stipulated norms as the next step after publishing in a journal. We shall depute a team of specialized research professionals who will render their services for elevating your researches to next higher level, which is worldwide open standardization.

The FARSM member can apply for grading and certification of standards of their educational and Institutional Degrees to Open Association of Research, Society U.S.A. Once you are designated as FARSM, you may send us a scanned copy of all of your credentials. OARS will verify, grade and certify them. This will be based on your academic records, quality of research papers published by you, and some more criteria. After certification of all your credentials by OARS, they will be published on your Fellow Profile link on website <https://associationofresearch.org> which will be helpful to upgrade the dignity.



The FARSM members can avail the benefits of free research podcasting in Global Research Radio with their research documents. After publishing the work, (including published elsewhere worldwide with proper authorization) you can upload your research paper with your recorded voice or you can utilize chargeable services of our professional RJs to record your paper in their voice on request.



The FARSM member also entitled to get the benefits of free research podcasting of their research documents through video clips. We can also streamline your conference videos and display your slides/ online slides and online research video clips at reasonable charges, on request.





The FARSM is eligible to earn from sales proceeds of his/her researches/reference/review Books or literature, while publishing with Global Journals. The FARSS can decide whether he/she would like to publish his/her research in a closed manner. In this case, whenever readers purchase that individual research paper for reading, maximum 60% of its profit earned as royalty by Global Journals, will be credited to his/her bank account. The entire entitled amount will be credited to his/her bank account exceeding limit of minimum fixed balance. There is no minimum time limit for collection. The FARSM member can decide its price and we can help in making the right decision.

The FARSM member is eligible to join as a paid peer reviewer at Global Journals Incorporation (USA) and can get remuneration of 15% of author fees, taken from the author of a respective paper. After reviewing 5 or more papers you can request to transfer the amount to your bank account.



## MEMBER OF ASSOCIATION OF RESEARCH SOCIETY IN MEDICAL (MARSM)

The ' MARSM ' title is accorded to a selected professional after the approval of the Editor-in-Chief / Editorial Board Members/Dean.

The “MARSM” is a dignified ornament which is accorded to a person’s name viz. Dr. John E. Hall, Ph.D., MARSM or William Walldroff, M.S., MARSM.



MARSM accrediting is an honor. It authenticates your research activities. After becoming MARSM, you can add 'MARSM' title with your name as you use this recognition as additional suffix to your status. This will definitely enhance and add more value and repute to your name. You may use it on your professional Counseling Materials such as CV, Resume, Visiting Card and Name Plate etc.

*The following benefits can be availed by you only for next three years from the date of certification.*



MARSM designated members are entitled to avail a 25% discount while publishing their research papers (of a single author) in Global Journals Inc., if the same is accepted by our Editorial Board and Peer Reviewers. If you are a main author or co-author of a group of authors, you will get discount of 10%.

As MARSM, you will be given a renowned, secure and free professional email address with 30 GB of space e.g. [johnhall@globaljournals.org](mailto:johnhall@globaljournals.org). This will include Webmail, Spam Assassin, Email Forwarders, Auto-Responders, Email Delivery Route tracing, etc.





We shall provide you intimation regarding launching of e-version of journal of your stream time to time. This may be utilized in your library for the enrichment of knowledge of your students as well as it can also be helpful for the concerned faculty members.

The MARSM member can apply for approval, grading and certification of standards of their educational and Institutional Degrees to Open Association of Research, Society U.S.A.



Once you are designated as MARSM, you may send us a scanned copy of all of your credentials. OARS will verify, grade and certify them. This will be based on your academic records, quality of research papers published by you, and some more criteria.

It is mandatory to read all terms and conditions carefully.



## AUXILIARY MEMBERSHIPS

### Institutional Fellow of Open Association of Research Society (USA) - OARS (USA)

Global Journals Incorporation (USA) is accredited by Open Association of Research Society, U.S.A (OARS) and in turn, affiliates research institutions as “Institutional Fellow of Open Association of Research Society” (IFOARS).

The “FARSC” is a dignified title which is accorded to a person’s name viz. Dr. John E. Hall, Ph.D., FARSC or William Walldroff, M.S., FARSC.



The IFOARS institution is entitled to form a Board comprised of one Chairperson and three to five board members preferably from different streams. The Board will be recognized as “Institutional Board of Open Association of Research Society”-(IBOARS).

*The Institute will be entitled to following benefits:*



The IBOARS can initially review research papers of their institute and recommend them to publish with respective journal of Global Journals. It can also review the papers of other institutions after obtaining our consent. The second review will be done by peer reviewer of Global Journals Incorporation (USA). The Board is at liberty to appoint a peer reviewer with the approval of chairperson after consulting us.

The author fees of such paper may be waived off up to 40%.

The Global Journals Incorporation (USA) at its discretion can also refer double blind peer reviewed paper at their end to the board for the verification and to get recommendation for final stage of acceptance of publication.



The IBOARS can organize symposium/seminar/conference in their country on behalf of Global Journals Incorporation (USA)-OARS (USA). The terms and conditions can be discussed separately.

The Board can also play vital role by exploring and giving valuable suggestions regarding the Standards of “Open Association of Research Society, U.S.A (OARS)” so that proper amendment can take place for the benefit of entire research community. We shall provide details of particular standard only on receipt of request from the Board.



Journals Research  
inducing researches

The board members can also join us as Individual Fellow with 40% discount on total fees applicable to Individual Fellow. They will be entitled to avail all the benefits as declared. Please visit Individual Fellow-sub menu of GlobalJournals.org to have more relevant details.



We shall provide you intimation regarding launching of e-version of journal of your stream time to time. This may be utilized in your library for the enrichment of knowledge of your students as well as it can also be helpful for the concerned faculty members.



After nomination of your institution as “Institutional Fellow” and constantly functioning successfully for one year, we can consider giving recognition to your institute to function as Regional/Zonal office on our behalf.

The board can also take up the additional allied activities for betterment after our consultation.

### **The following entitlements are applicable to individual Fellows:**

Open Association of Research Society, U.S.A (OARS) By-laws states that an individual Fellow may use the designations as applicable, or the corresponding initials. The Credentials of individual Fellow and Associate designations signify that the individual has gained knowledge of the fundamental concepts. One is magnanimous and proficient in an expertise course covering the professional code of conduct, and follows recognized standards of practice.



Open Association of Research Society (US)/ Global Journals Incorporation (USA), as described in Corporate Statements, are educational, research publishing and professional membership organizations. Achieving our individual Fellow or Associate status is based mainly on meeting stated educational research requirements.

Disbursement of 40% Royalty earned through Global Journals : Researcher = 50%, Peer Reviewer = 37.50%, Institution = 12.50% E.g. Out of 40%, the 20% benefit should be passed on to researcher, 15 % benefit towards remuneration should be given to a reviewer and remaining 5% is to be retained by the institution.



We shall provide print version of 12 issues of any three journals [as per your requirement] out of our 38 journals worth \$ 2376 USD.

### **Other:**

**The individual Fellow and Associate designations accredited by Open Association of Research Society (US) credentials signify guarantees following achievements:**

- The professional accredited with Fellow honor, is entitled to various benefits viz. name, fame, honor, regular flow of income, secured bright future, social status etc.





- In addition to above, if one is single author, then entitled to 40% discount on publishing research paper and can get 10% discount if one is co-author or main author among group of authors.
- The Fellow can organize symposium/seminar/conference on behalf of Global Journals Incorporation (USA) and he/she can also attend the same organized by other institutes on behalf of Global Journals.
- The Fellow can become member of Editorial Board Member after completing 3yrs.
- The Fellow can earn 60% of sales proceeds from the sale of reference/review books/literature/publishing of research paper.
- Fellow can also join as paid peer reviewer and earn 15% remuneration of author charges and can also get an opportunity to join as member of the Editorial Board of Global Journals Incorporation (USA)
- • This individual has learned the basic methods of applying those concepts and techniques to common challenging situations. This individual has further demonstrated an in-depth understanding of the application of suitable techniques to a particular area of research practice.

## Note :

//

- In future, if the board feels the necessity to change any board member, the same can be done with the consent of the chairperson along with anyone board member without our approval.
- In case, the chairperson needs to be replaced then consent of 2/3rd board members are required and they are also required to jointly pass the resolution copy of which should be sent to us. In such case, it will be compulsory to obtain our approval before replacement.
- In case of "Difference of Opinion [if any]" among the Board members, our decision will be final and binding to everyone.

//



## PROCESS OF SUBMISSION OF RESEARCH PAPER

The Area or field of specialization may or may not be of any category as mentioned in 'Scope of Journal' menu of the GlobalJournals.org website. There are 37 Research Journal categorized with Six parental Journals GJCST, GJMR, GJRE, GJMBR, GJSFR, GJHSS. For Authors should prefer the mentioned categories. There are three widely used systems UDC, DDC and LCC. The details are available as 'Knowledge Abstract' at Home page. The major advantage of this coding is that, the research work will be exposed to and shared with all over the world as we are being abstracted and indexed worldwide.

The paper should be in proper format. The format can be downloaded from first page of 'Author Guideline' Menu. The Author is expected to follow the general rules as mentioned in this menu. The paper should be written in MS-Word Format (\*.DOC,\*.DOCX).

The Author can submit the paper either online or offline. The authors should prefer online submission.Online Submission: There are three ways to submit your paper:

**(A) (I) First, register yourself using top right corner of Home page then Login. If you are already registered, then login using your username and password.**

**(II) Choose corresponding Journal.**

**(III) Click 'Submit Manuscript'. Fill required information and Upload the paper.**

**(B) If you are using Internet Explorer, then Direct Submission through Homepage is also available.**

**(C) If these two are not convenient, and then email the paper directly to dean@globaljournals.org.**

Offline Submission: Author can send the typed form of paper by Post. However, online submission should be preferred.



# PREFERRED AUTHOR GUIDELINES

## MANUSCRIPT STYLE INSTRUCTION (Must be strictly followed)

Page Size: 8.27" X 11"

- Left Margin: 0.65
- Right Margin: 0.65
- Top Margin: 0.75
- Bottom Margin: 0.75
- Font type of all text should be Swis 721 Lt BT.
- Paper Title should be of Font Size 24 with one Column section.
- Author Name in Font Size of 11 with one column as of Title.
- Abstract Font size of 9 Bold, "Abstract" word in Italic Bold.
- Main Text: Font size 10 with justified two columns section
- Two Column with Equal Column with of 3.38 and Gaping of .2
- First Character must be three lines Drop capped.
- Paragraph before Spacing of 1 pt and After of 0 pt.
- Line Spacing of 1 pt
- Large Images must be in One Column
- Numbering of First Main Headings (Heading 1) must be in Roman Letters, Capital Letter, and Font Size of 10.
- Numbering of Second Main Headings (Heading 2) must be in Alphabets, Italic, and Font Size of 10.

**You can use your own standard format also.**

### Author Guidelines:

1. General,
2. Ethical Guidelines,
3. Submission of Manuscripts,
4. Manuscript's Category,
5. Structure and Format of Manuscript,
6. After Acceptance.

### 1. GENERAL

Before submitting your research paper, one is advised to go through the details as mentioned in following heads. It will be beneficial, while peer reviewer justify your paper for publication.

### Scope

The Global Journals Inc. (US) welcome the submission of original paper, review paper, survey article relevant to the all the streams of Philosophy and knowledge. The Global Journals Inc. (US) is parental platform for Global Journal of Computer Science and Technology, Researches in Engineering, Medical Research, Science Frontier Research, Human Social Science, Management, and Business organization. The choice of specific field can be done otherwise as following in Abstracting and Indexing Page on this Website. As the all Global

Journals Inc. (US) are being abstracted and indexed (in process) by most of the reputed organizations. Topics of only narrow interest will not be accepted unless they have wider potential or consequences.

## 2. ETHICAL GUIDELINES

Authors should follow the ethical guidelines as mentioned below for publication of research paper and research activities.

Papers are accepted on strict understanding that the material in whole or in part has not been, nor is being, considered for publication elsewhere. If the paper once accepted by Global Journals Inc. (US) and Editorial Board, will become the copyright of the Global Journals Inc. (US).

**Authorship: The authors and coauthors should have active contribution to conception design, analysis and interpretation of findings. They should critically review the contents and drafting of the paper. All should approve the final version of the paper before submission**

The Global Journals Inc. (US) follows the definition of authorship set up by the Global Academy of Research and Development. According to the Global Academy of R&D authorship, criteria must be based on:

- 1) Substantial contributions to conception and acquisition of data, analysis and interpretation of the findings.
- 2) Drafting the paper and revising it critically regarding important academic content.
- 3) Final approval of the version of the paper to be published.

All authors should have been credited according to their appropriate contribution in research activity and preparing paper. Contributors who do not match the criteria as authors may be mentioned under Acknowledgement.

Acknowledgements: Contributors to the research other than authors credited should be mentioned under acknowledgement. The specifications of the source of funding for the research if appropriate can be included. Suppliers of resources may be mentioned along with address.

**Appeal of Decision: The Editorial Board's decision on publication of the paper is final and cannot be appealed elsewhere.**

**Permissions: It is the author's responsibility to have prior permission if all or parts of earlier published illustrations are used in this paper.**

Please mention proper reference and appropriate acknowledgements wherever expected.

If all or parts of previously published illustrations are used, permission must be taken from the copyright holder concerned. It is the author's responsibility to take these in writing.

Approval for reproduction/modification of any information (including figures and tables) published elsewhere must be obtained by the authors/copyright holders before submission of the manuscript. Contributors (Authors) are responsible for any copyright fee involved.

## 3. SUBMISSION OF MANUSCRIPTS

Manuscripts should be uploaded via this online submission page. The online submission is most efficient method for submission of papers, as it enables rapid distribution of manuscripts and consequently speeds up the review procedure. It also enables authors to know the status of their own manuscripts by emailing us. Complete instructions for submitting a paper is available below.

Manuscript submission is a systematic procedure and little preparation is required beyond having all parts of your manuscript in a given format and a computer with an Internet connection and a Web browser. Full help and instructions are provided on-screen. As an author, you will be prompted for login and manuscript details as Field of Paper and then to upload your manuscript file(s) according to the instructions.



To avoid postal delays, all transaction is preferred by e-mail. A finished manuscript submission is confirmed by e-mail immediately and your paper enters the editorial process with no postal delays. When a conclusion is made about the publication of your paper by our Editorial Board, revisions can be submitted online with the same procedure, with an occasion to view and respond to all comments.

Complete support for both authors and co-author is provided.

#### 4. MANUSCRIPT'S CATEGORY

Based on potential and nature, the manuscript can be categorized under the following heads:

Original research paper: Such papers are reports of high-level significant original research work.

Review papers: These are concise, significant but helpful and decisive topics for young researchers.

Research articles: These are handled with small investigation and applications

Research letters: The letters are small and concise comments on previously published matters.

#### 5. STRUCTURE AND FORMAT OF MANUSCRIPT

The recommended size of original research paper is less than seven thousand words, review papers fewer than seven thousands words also. Preparation of research paper or how to write research paper, are major hurdle, while writing manuscript. The research articles and research letters should be fewer than three thousand words, the structure original research paper; sometime review paper should be as follows:

**Papers:** These are reports of significant research (typically less than 7000 words equivalent, including tables, figures, references), and comprise:

- (a) Title should be relevant and commensurate with the theme of the paper.
- (b) A brief Summary, "Abstract" (less than 150 words) containing the major results and conclusions.
- (c) Up to ten keywords, that precisely identifies the paper's subject, purpose, and focus.
- (d) An Introduction, giving necessary background excluding subheadings; objectives must be clearly declared.
- (e) Resources and techniques with sufficient complete experimental details (wherever possible by reference) to permit repetition; sources of information must be given and numerical methods must be specified by reference, unless non-standard.
- (f) Results should be presented concisely, by well-designed tables and/or figures; the same data may not be used in both; suitable statistical data should be given. All data must be obtained with attention to numerical detail in the planning stage. As reproduced design has been recognized to be important to experiments for a considerable time, the Editor has decided that any paper that appears not to have adequate numerical treatments of the data will be returned un-refereed;
- (g) Discussion should cover the implications and consequences, not just recapitulating the results; conclusions should be summarizing.
- (h) Brief Acknowledgements.
- (i) References in the proper form.

Authors should very cautiously consider the preparation of papers to ensure that they communicate efficiently. Papers are much more likely to be accepted, if they are cautiously designed and laid out, contain few or no errors, are summarizing, and be conventional to the approach and instructions. They will in addition, be published with much less delays than those that require much technical and editorial correction.





The Editorial Board reserves the right to make literary corrections and to make suggestions to improve briefness.

It is vital, that authors take care in submitting a manuscript that is written in simple language and adheres to published guidelines.

## Format

*Language: The language of publication is UK English. Authors, for whom English is a second language, must have their manuscript efficiently edited by an English-speaking person before submission to make sure that, the English is of high excellence. It is preferable, that manuscripts should be professionally edited.*

Standard Usage, Abbreviations, and Units: Spelling and hyphenation should be conventional to The Concise Oxford English Dictionary. Statistics and measurements should at all times be given in figures, e.g. 16 min, except for when the number begins a sentence. When the number does not refer to a unit of measurement it should be spelt in full unless, it is 160 or greater.

Abbreviations supposed to be used carefully. The abbreviated name or expression is supposed to be cited in full at first usage, followed by the conventional abbreviation in parentheses.

Metric SI units are supposed to generally be used excluding where they conflict with current practice or are confusing. For illustration, 1.4 l rather than  $1.4 \times 10^{-3} \text{ m}^3$ , or 4 mm somewhat than  $4 \times 10^{-3} \text{ m}$ . Chemical formula and solutions must identify the form used, e.g. anhydrous or hydrated, and the concentration must be in clearly defined units. Common species names should be followed by underlines at the first mention. For following use the generic name should be constricted to a single letter, if it is clear.

## Structure

All manuscripts submitted to Global Journals Inc. (US), ought to include:

**Title:** The title page must carry an instructive title that reflects the content, a running title (less than 45 characters together with spaces), names of the authors and co-authors, and the place(s) wherever the work was carried out. The full postal address in addition with the e-mail address of related author must be given. Up to eleven keywords or very brief phrases have to be given to help data retrieval, mining and indexing.

*Abstract, used in Original Papers and Reviews:*

### Optimizing Abstract for Search Engines

Many researchers searching for information online will use search engines such as Google, Yahoo or similar. By optimizing your paper for search engines, you will amplify the chance of someone finding it. This in turn will make it more likely to be viewed and/or cited in a further work. Global Journals Inc. (US) have compiled these guidelines to facilitate you to maximize the web-friendliness of the most public part of your paper.

### Key Words

A major linchpin in research work for the writing research paper is the keyword search, which one will employ to find both library and Internet resources.

One must be persistent and creative in using keywords. An effective keyword search requires a strategy and planning a list of possible keywords and phrases to try.

Search engines for most searches, use Boolean searching, which is somewhat different from Internet searches. The Boolean search uses "operators," words (and, or, not, and near) that enable you to expand or narrow your affords. Tips for research paper while preparing research paper are very helpful guideline of research paper.

Choice of key words is first tool of tips to write research paper. Research paper writing is an art. A few tips for deciding as strategically as possible about keyword search:



- One should start brainstorming lists of possible keywords before even begin searching. Think about the most important concepts related to research work. Ask, "What words would a source have to include to be truly valuable in research paper?" Then consider synonyms for the important words.
- It may take the discovery of only one relevant paper to let steer in the right keyword direction because in most databases, the keywords under which a research paper is abstracted are listed with the paper.
- One should avoid outdated words.

Keywords are the key that opens a door to research work sources. Keyword searching is an art in which researcher's skills are bound to improve with experience and time.

Numerical Methods: Numerical methods used should be clear and, where appropriate, supported by references.

*Acknowledgements: Please make these as concise as possible.*

## References

References follow the Harvard scheme of referencing. References in the text should cite the authors' names followed by the time of their publication, unless there are three or more authors when simply the first author's name is quoted followed by et al. unpublished work has to only be cited where necessary, and only in the text. Copies of references in press in other journals have to be supplied with submitted typescripts. It is necessary that all citations and references be carefully checked before submission, as mistakes or omissions will cause delays.

References to information on the World Wide Web can be given, but only if the information is available without charge to readers on an official site. Wikipedia and Similar websites are not allowed where anyone can change the information. Authors will be asked to make available electronic copies of the cited information for inclusion on the Global Journals Inc. (US) homepage at the judgment of the Editorial Board.

The Editorial Board and Global Journals Inc. (US) recommend that, citation of online-published papers and other material should be done via a DOI (digital object identifier). If an author cites anything, which does not have a DOI, they run the risk of the cited material not being noticeable.

The Editorial Board and Global Journals Inc. (US) recommend the use of a tool such as Reference Manager for reference management and formatting.

## Tables, Figures and Figure Legends

*Tables: Tables should be few in number, cautiously designed, uncrowned, and include only essential data. Each must have an Arabic number, e.g. Table 4, a self-explanatory caption and be on a separate sheet. Vertical lines should not be used.*

*Figures: Figures are supposed to be submitted as separate files. Always take in a citation in the text for each figure using Arabic numbers, e.g. Fig. 4. Artwork must be submitted online in electronic form by e-mailing them.*

## Preparation of Electronic Figures for Publication

Even though low quality images are sufficient for review purposes, print publication requires high quality images to prevent the final product being blurred or fuzzy. Submit (or e-mail) EPS (line art) or TIFF (halftone/photographs) files only. MS PowerPoint and Word Graphics are unsuitable for printed pictures. Do not use pixel-oriented software. Scans (TIFF only) should have a resolution of at least 350 dpi (halftone) or 700 to 1100 dpi (line drawings) in relation to the imitation size. Please give the data for figures in black and white or submit a Color Work Agreement Form. EPS files must be saved with fonts embedded (and with a TIFF preview, if possible).

For scanned images, the scanning resolution (at final image size) ought to be as follows to ensure good reproduction: line art: >650 dpi; halftones (including gel photographs) : >350 dpi; figures containing both halftone and line images: >650 dpi.



**Color Charges:** It is the rule of the Global Journals Inc. (US) for authors to pay the full cost for the reproduction of their color artwork. Hence, please note that, if there is color artwork in your manuscript when it is accepted for publication, we would require you to complete and return a color work agreement form before your paper can be published.

*Figure Legends: Self-explanatory legends of all figures should be incorporated separately under the heading 'Legends to Figures'. In the full-text online edition of the journal, figure legends may possibly be truncated in abbreviated links to the full screen version. Therefore, the first 100 characters of any legend should notify the reader, about the key aspects of the figure.*

## **6. AFTER ACCEPTANCE**

Upon approval of a paper for publication, the manuscript will be forwarded to the dean, who is responsible for the publication of the Global Journals Inc. (US).

### **6.1 Proof Corrections**

The corresponding author will receive an e-mail alert containing a link to a website or will be attached. A working e-mail address must therefore be provided for the related author.

Acrobat Reader will be required in order to read this file. This software can be downloaded

(Free of charge) from the following website:

[www.adobe.com/products/acrobat/readstep2.html](http://www.adobe.com/products/acrobat/readstep2.html). This will facilitate the file to be opened, read on screen, and printed out in order for any corrections to be added. Further instructions will be sent with the proof.

Proofs must be returned to the dean at [dean@globaljournals.org](mailto:dean@globaljournals.org) within three days of receipt.

As changes to proofs are costly, we inquire that you only correct typesetting errors. All illustrations are retained by the publisher. Please note that the authors are responsible for all statements made in their work, including changes made by the copy editor.

### **6.2 Early View of Global Journals Inc. (US) (Publication Prior to Print)**

The Global Journals Inc. (US) are enclosed by our publishing's Early View service. Early View articles are complete full-text articles sent in advance of their publication. Early View articles are absolute and final. They have been completely reviewed, revised and edited for publication, and the authors' final corrections have been incorporated. Because they are in final form, no changes can be made after sending them. The nature of Early View articles means that they do not yet have volume, issue or page numbers, so Early View articles cannot be cited in the conventional way.

### **6.3 Author Services**

Online production tracking is available for your article through Author Services. Author Services enables authors to track their article - once it has been accepted - through the production process to publication online and in print. Authors can check the status of their articles online and choose to receive automated e-mails at key stages of production. The authors will receive an e-mail with a unique link that enables them to register and have their article automatically added to the system. Please ensure that a complete e-mail address is provided when submitting the manuscript.

### **6.4 Author Material Archive Policy**

Please note that if not specifically requested, publisher will dispose off hardcopy & electronic information submitted, after the two months of publication. If you require the return of any information submitted, please inform the Editorial Board or dean as soon as possible.

### **6.5 Offprint and Extra Copies**

A PDF offprint of the online-published article will be provided free of charge to the related author, and may be distributed according to the Publisher's terms and conditions. Additional paper offprint may be ordered by emailing us at: [editor@globaljournals.org](mailto:editor@globaljournals.org).



Before start writing a good quality Computer Science Research Paper, let us first understand what is Computer Science Research Paper? So, Computer Science Research Paper is the paper which is written by professionals or scientists who are associated to Computer Science and Information Technology, or doing research study in these areas. If you are novel to this field then you can consult about this field from your supervisor or guide.

#### TECHNIQUES FOR WRITING A GOOD QUALITY RESEARCH PAPER:

**1. Choosing the topic:** In most cases, the topic is searched by the interest of author but it can be also suggested by the guides. You can have several topics and then you can judge that in which topic or subject you are finding yourself most comfortable. This can be done by asking several questions to yourself, like Will I be able to carry our search in this area? Will I find all necessary recourses to accomplish the search? Will I be able to find all information in this field area? If the answer of these types of questions will be "Yes" then you can choose that topic. In most of the cases, you may have to conduct the surveys and have to visit several places because this field is related to Computer Science and Information Technology. Also, you may have to do a lot of work to find all rise and falls regarding the various data of that subject. Sometimes, detailed information plays a vital role, instead of short information.

**2. Evaluators are human:** First thing to remember that evaluators are also human being. They are not only meant for rejecting a paper. They are here to evaluate your paper. So, present your Best.

**3. Think Like Evaluators:** If you are in a confusion or getting demotivated that your paper will be accepted by evaluators or not, then think and try to evaluate your paper like an Evaluator. Try to understand that what an evaluator wants in your research paper and automatically you will have your answer.

**4. Make blueprints of paper:** The outline is the plan or framework that will help you to arrange your thoughts. It will make your paper logical. But remember that all points of your outline must be related to the topic you have chosen.

**5. Ask your Guides:** If you are having any difficulty in your research, then do not hesitate to share your difficulty to your guide (if you have any). They will surely help you out and resolve your doubts. If you can't clarify what exactly you require for your work then ask the supervisor to help you with the alternative. He might also provide you the list of essential readings.

**6. Use of computer is recommended:** As you are doing research in the field of Computer Science, then this point is quite obvious.

**7. Use right software:** Always use good quality software packages. If you are not capable to judge good software then you can lose quality of your paper unknowingly. There are various software programs available to help you, which you can get through Internet.

**8. Use the Internet for help:** An excellent start for your paper can be by using the Google. It is an excellent search engine, where you can have your doubts resolved. You may also read some answers for the frequent question how to write my research paper or find model research paper. From the internet library you can download books. If you have all required books make important reading selecting and analyzing the specified information. Then put together research paper sketch out.

**9. Use and get big pictures:** Always use encyclopedias, Wikipedia to get pictures so that you can go into the depth.

**10. Bookmarks are useful:** When you read any book or magazine, you generally use bookmarks, right! It is a good habit, which helps to not to lose your continuity. You should always use bookmarks while searching on Internet also, which will make your search easier.

**11. Revise what you wrote:** When you write anything, always read it, summarize it and then finalize it.



**12. Make all efforts:** Make all efforts to mention what you are going to write in your paper. That means always have a good start. Try to mention everything in introduction, that what is the need of a particular research paper. Polish your work by good skill of writing and always give an evaluator, what he wants.

**13. Have backups:** When you are going to do any important thing like making research paper, you should always have backup copies of it either in your computer or in paper. This will help you to not to lose any of your important.

**14. Produce good diagrams of your own:** Always try to include good charts or diagrams in your paper to improve quality. Using several and unnecessary diagrams will degrade the quality of your paper by creating "hotchpotch." So always, try to make and include those diagrams, which are made by your own to improve readability and understandability of your paper.

**15. Use of direct quotes:** When you do research relevant to literature, history or current affairs then use of quotes become essential but if study is relevant to science then use of quotes is not preferable.

**16. Use proper verb tense:** Use proper verb tenses in your paper. Use past tense, to present those events that happened. Use present tense to indicate events that are going on. Use future tense to indicate future happening events. Use of improper and wrong tenses will confuse the evaluator. Avoid the sentences that are incomplete.

**17. Never use online paper:** If you are getting any paper on Internet, then never use it as your research paper because it might be possible that evaluator has already seen it or maybe it is outdated version.

**18. Pick a good study spot:** To do your research studies always try to pick a spot, which is quiet. Every spot is not for studies. Spot that suits you choose it and proceed further.

**19. Know what you know:** Always try to know, what you know by making objectives. Else, you will be confused and cannot achieve your target.

**20. Use good quality grammar:** Always use a good quality grammar and use words that will throw positive impact on evaluator. Use of good quality grammar does not mean to use tough words, that for each word the evaluator has to go through dictionary. Do not start sentence with a conjunction. Do not fragment sentences. Eliminate one-word sentences. Ignore passive voice. Do not ever use a big word when a diminutive one would suffice. Verbs have to be in agreement with their subjects. Prepositions are not expressions to finish sentences with. It is incorrect to ever divide an infinitive. Avoid clichés like the disease. Also, always shun irritating alliteration. Use language that is simple and straight forward. put together a neat summary.

**21. Arrangement of information:** Each section of the main body should start with an opening sentence and there should be a changeover at the end of the section. Give only valid and powerful arguments to your topic. You may also maintain your arguments with records.

**22. Never start in last minute:** Always start at right time and give enough time to research work. Leaving everything to the last minute will degrade your paper and spoil your work.

**23. Multitasking in research is not good:** Doing several things at the same time proves bad habit in case of research activity. Research is an area, where everything has a particular time slot. Divide your research work in parts and do particular part in particular time slot.

**24. Never copy others' work:** Never copy others' work and give it your name because if evaluator has seen it anywhere you will be in trouble.

**25. Take proper rest and food:** No matter how many hours you spend for your research activity, if you are not taking care of your health then all your efforts will be in vain. For a quality research, study is must, and this can be done by taking proper rest and food.

**26. Go for seminars:** Attend seminars if the topic is relevant to your research area. Utilize all your resources.



**27. Refresh your mind after intervals:** Try to give rest to your mind by listening to soft music or by sleeping in intervals. This will also improve your memory.

**28. Make colleagues:** Always try to make colleagues. No matter how sharper or intelligent you are, if you make colleagues you can have several ideas, which will be helpful for your research.

**29. Think technically:** Always think technically. If anything happens, then search its reasons, its benefits, and demerits.

**30. Think and then print:** When you will go to print your paper, notice that tables are not be split, headings are not detached from their descriptions, and page sequence is maintained.

**31. Adding unnecessary information:** Do not add unnecessary information, like, I have used MS Excel to draw graph. Do not add irrelevant and inappropriate material. These all will create superfluous. Foreign terminology and phrases are not apropos. One should NEVER take a broad view. Analogy in script is like feathers on a snake. Not at all use a large word when a very small one would be sufficient. Use words properly, regardless of how others use them. Remove quotations. Puns are for kids, not grunt readers. Amplification is a billion times of inferior quality than sarcasm.

**32. Never oversimplify everything:** To add material in your research paper, never go for oversimplification. This will definitely irritate the evaluator. Be more or less specific. Also too, by no means, ever use rhythmic redundancies. Contractions aren't essential and shouldn't be there used. Comparisons are as terrible as clichés. Give up ampersands and abbreviations, and so on. Remove commas, that are, not necessary. Parenthetical words however should be together with this in commas. Understatement is all the time the complete best way to put onward earth-shaking thoughts. Give a detailed literary review.

**33. Report concluded results:** Use concluded results. From raw data, filter the results and then conclude your studies based on measurements and observations taken. Significant figures and appropriate number of decimal places should be used. Parenthetical remarks are prohibitive. Proofread carefully at final stage. In the end give outline to your arguments. Spot out perspectives of further study of this subject. Justify your conclusion by at the bottom of them with sufficient justifications and examples.

**34. After conclusion:** Once you have concluded your research, the next most important step is to present your findings. Presentation is extremely important as it is the definite medium through which your research is going to be in print to the rest of the crowd. Care should be taken to categorize your thoughts well and present them in a logical and neat manner. A good quality research paper format is essential because it serves to highlight your research paper and bring to light all necessary aspects in your research.

## INFORMAL GUIDELINES OF RESEARCH PAPER WRITING

### Key points to remember:

- Submit all work in its final form.
- Write your paper in the form, which is presented in the guidelines using the template.
- Please note the criterion for grading the final paper by peer-reviewers.

### Final Points:

A purpose of organizing a research paper is to let people to interpret your effort selectively. The journal requires the following sections, submitted in the order listed, each section to start on a new page.

The introduction will be compiled from reference matter and will reflect the design processes or outline of basis that direct you to make study. As you will carry out the process of study, the method and process section will be constructed as like that. The result segment will show related statistics in nearly sequential order and will direct the reviewers next to the similar intellectual paths throughout the data that you took to carry out your study. The discussion section will provide understanding of the data and projections as to the implication of the results. The use of good quality references all through the paper will give the effort trustworthiness by representing an alertness of prior workings.





Writing a research paper is not an easy job no matter how trouble-free the actual research or concept. Practice, excellent preparation, and controlled record keeping are the only means to make straightforward the progression.

### **General style:**

Specific editorial column necessities for compliance of a manuscript will always take over from directions in these general guidelines.

To make a paper clear

- Adhere to recommended page limits

Mistakes to evade

- Insertion a title at the foot of a page with the subsequent text on the next page
- Separating a table/chart or figure - impound each figure/table to a single page
- Submitting a manuscript with pages out of sequence

In every sections of your document

- Use standard writing style including articles ("a", "the," etc.)
- Keep on paying attention on the research topic of the paper
- Use paragraphs to split each significant point (excluding for the abstract)
- Align the primary line of each section
- Present your points in sound order
- Use present tense to report well accepted
- Use past tense to describe specific results
- Shun familiar wording, don't address the reviewer directly, and don't use slang, slang language, or superlatives
- Shun use of extra pictures - include only those figures essential to presenting results

### **Title Page:**

Choose a revealing title. It should be short. It should not have non-standard acronyms or abbreviations. It should not exceed two printed lines. It should include the name(s) and address (es) of all authors.



### Abstract:

The summary should be two hundred words or less. It should briefly and clearly explain the key findings reported in the manuscript-- must have precise statistics. It should not have abnormal acronyms or abbreviations. It should be logical in itself. Shun citing references at this point.

An abstract is a brief distinct paragraph summary of finished work or work in development. In a minute or less a reviewer can be taught the foundation behind the study, common approach to the problem, relevant results, and significant conclusions or new questions.

Write your summary when your paper is completed because how can you write the summary of anything which is not yet written? Wealth of terminology is very essential in abstract. Yet, use comprehensive sentences and do not let go readability for briefness. You can maintain it succinct by phrasing sentences so that they provide more than lone rationale. The author can at this moment go straight to shortening the outcome. Sum up the study, with the subsequent elements in any summary. Try to maintain the initial two items to no more than one ruling each.

- Reason of the study - theory, overall issue, purpose
- Fundamental goal
- To the point depiction of the research
- Consequences, including definite statistics - if the consequences are quantitative in nature, account quantitative data; results of any numerical analysis should be reported
- Significant conclusions or questions that track from the research(es)

### Approach:

- Single section, and succinct
- As a outline of job done, it is always written in past tense
- A conceptual should situate on its own, and not submit to any other part of the paper such as a form or table
- Center on shortening results - bound background information to a verdict or two, if completely necessary
- What you account in an conceptual must be regular with what you reported in the manuscript
- Exact spelling, clearness of sentences and phrases, and appropriate reporting of quantities (proper units, important statistics) are just as significant in an abstract as they are anywhere else

### Introduction:

The **Introduction** should "introduce" the manuscript. The reviewer should be presented with sufficient background information to be capable to comprehend and calculate the purpose of your study without having to submit to other works. The basis for the study should be offered. Give most important references but shun difficult to make a comprehensive appraisal of the topic. In the introduction, describe the problem visibly. If the problem is not acknowledged in a logical, reasonable way, the reviewer will have no attention in your result. Speak in common terms about techniques used to explain the problem, if needed, but do not present any particulars about the protocols here. Following approach can create a valuable beginning:

- Explain the value (significance) of the study
- Shield the model - why did you employ this particular system or method? What is its compensation? You strength remark on its appropriateness from a abstract point of vision as well as point out sensible reasons for using it.
- Present a justification. Status your particular theory (es) or aim(s), and describe the logic that led you to choose them.
- Very for a short time explain the tentative propose and how it skilled the declared objectives.

### Approach:

- Use past tense except for when referring to recognized facts. After all, the manuscript will be submitted after the entire job is done.
- Sort out your thoughts; manufacture one key point with every section. If you make the four points listed above, you will need a least of four paragraphs.



- Present surroundings information only as desirable in order hold up a situation. The reviewer does not desire to read the whole thing you know about a topic.
- Shape the theory/purpose specifically - do not take a broad view.
- As always, give awareness to spelling, simplicity and correctness of sentences and phrases.

#### **Procedures (Methods and Materials):**

This part is supposed to be the easiest to carve if you have good skills. A sound written Procedures segment allows a capable scientist to replacement your results. Present precise information about your supplies. The suppliers and clarity of reagents can be helpful bits of information. Present methods in sequential order but linked methodologies can be grouped as a segment. Be concise when relating the protocols. Attempt for the least amount of information that would permit another capable scientist to spare your outcome but be cautious that vital information is integrated. The use of subheadings is suggested and ought to be synchronized with the results section. When a technique is used that has been well described in another object, mention the specific item describing a way but draw the basic principle while stating the situation. The purpose is to text all particular resources and broad procedures, so that another person may use some or all of the methods in one more study or referee the scientific value of your work. It is not to be a step by step report of the whole thing you did, nor is a methods section a set of orders.

#### **Materials:**

- Explain materials individually only if the study is so complex that it saves liberty this way.
- Embrace particular materials, and any tools or provisions that are not frequently found in laboratories.
- Do not take in frequently found.
- If use of a definite type of tools.
- Materials may be reported in a part section or else they may be recognized along with your measures.

#### **Methods:**

- Report the method (not particulars of each process that engaged the same methodology)
- Describe the method entirely
- To be succinct, present methods under headings dedicated to specific dealings or groups of measures
- Simplify - details how procedures were completed not how they were exclusively performed on a particular day.
- If well known procedures were used, account the procedure by name, possibly with reference, and that's all.

#### **Approach:**

- It is embarrassed or not possible to use vigorous voice when documenting methods with no using first person, which would focus the reviewer's interest on the researcher rather than the job. As a result when script up the methods most authors use third person passive voice.
- Use standard style in this and in every other part of the paper - avoid familiar lists, and use full sentences.

#### **What to keep away from**

- Resources and methods are not a set of information.
- Skip all descriptive information and surroundings - save it for the argument.
- Leave out information that is immaterial to a third party.

#### **Results:**

The principle of a results segment is to present and demonstrate your conclusion. Create this part a entirely objective details of the outcome, and save all understanding for the discussion.

The page length of this segment is set by the sum and types of data to be reported. Carry on to be to the point, by means of statistics and tables, if suitable, to present consequences most efficiently. You must obviously differentiate material that would usually be incorporated in a study editorial from any unprocessed data or additional appendix matter that would not be available. In fact, such matter should not be submitted at all except requested by the instructor.



## Content

- Sum up your conclusion in text and demonstrate them, if suitable, with figures and tables.
- In manuscript, explain each of your consequences, point the reader to remarks that are most appropriate.
- Present a background, such as by describing the question that was addressed by creation an exacting study.
- Explain results of control experiments and comprise remarks that are not accessible in a prescribed figure or table, if appropriate.
- Examine your data, then prepare the analyzed (transformed) data in the form of a figure (graph), table, or in manuscript form.

### What to stay away from

- Do not discuss or infer your outcome, report surroundings information, or try to explain anything.
- Not at all, take in raw data or intermediate calculations in a research manuscript.
- Do not present the similar data more than once.
- Manuscript should complement any figures or tables, not duplicate the identical information.
- Never confuse figures with tables - there is a difference.

### Approach

- As forever, use past tense when you submit to your results, and put the whole thing in a reasonable order.
- Put figures and tables, appropriately numbered, in order at the end of the report
- If you desire, you may place your figures and tables properly within the text of your results part.

### Figures and tables

- If you put figures and tables at the end of the details, make certain that they are visibly distinguished from any attach appendix materials, such as raw facts
- Despite of position, each figure must be numbered one after the other and complete with subtitle
- In spite of position, each table must be titled, numbered one after the other and complete with heading
- All figure and table must be adequately complete that it could situate on its own, divide from text

### Discussion:

The Discussion is expected the trickiest segment to write and describe. A lot of papers submitted for journal are discarded based on problems with the Discussion. There is no head of state for how long a argument should be. Position your understanding of the outcome visibly to lead the reviewer through your conclusions, and then finish the paper with a summing up of the implication of the study. The purpose here is to offer an understanding of your results and hold up for all of your conclusions, using facts from your research and generally accepted information, if suitable. The implication of result should be visibly described. Infer your data in the conversation in suitable depth. This means that when you clarify an observable fact you must explain mechanisms that may account for the observation. If your results vary from your prospect, make clear why that may have happened. If your results agree, then explain the theory that the proof supported. It is never suitable to just state that the data approved with prospect, and let it drop at that.

- Make a decision if each premise is supported, discarded, or if you cannot make a conclusion with assurance. Do not just dismiss a study or part of a study as "uncertain."
- Research papers are not acknowledged if the work is imperfect. Draw what conclusions you can based upon the results that you have, and take care of the study as a finished work
- You may propose future guidelines, such as how the experiment might be personalized to accomplish a new idea.
- Give details all of your remarks as much as possible, focus on mechanisms.
- Make a decision if the tentative design sufficiently addressed the theory, and whether or not it was correctly restricted.
- Try to present substitute explanations if sensible alternatives be present.
- One research will not counter an overall question, so maintain the large picture in mind, where do you go next? The best studies unlock new avenues of study. What questions remain?
- Recommendations for detailed papers will offer supplementary suggestions.

### Approach:

- When you refer to information, differentiate data generated by your own studies from available information
- Submit to work done by specific persons (including you) in past tense.
- Submit to generally acknowledged facts and main beliefs in present tense.



## THE ADMINISTRATION RULES

Please carefully note down following rules and regulation before submitting your Research Paper to Global Journals Inc. (US):

**Segment Draft and Final Research Paper:** You have to strictly follow the template of research paper. If it is not done your paper may get rejected.

- The **major constraint** is that you must independently make all content, tables, graphs, and facts that are offered in the paper. You must write each part of the paper wholly on your own. The Peer-reviewers need to identify your own perceptive of the concepts in your own terms. NEVER extract straight from any foundation, and never rephrase someone else's analysis.
- Do not give permission to anyone else to "PROOFREAD" your manuscript.
- **Methods to avoid Plagiarism is applied by us on every paper, if found guilty, you will be blacklisted by all of our collaborated research groups, your institution will be informed for this and strict legal actions will be taken immediately.)**
- To guard yourself and others from possible illegal use please do not permit anyone right to use to your paper and files.




CRITERION FOR GRADING A RESEARCH PAPER (COMPILATION)  
BY GLOBAL JOURNALS INC. (US)

Please note that following table is only a Grading of "Paper Compilation" and not on "Performed/Stated Research" whose grading solely depends on Individual Assigned Peer Reviewer and Editorial Board Member. These can be available only on request and after decision of Paper. This report will be the property of Global Journals Inc. (US).

Topics	Grades		
	A-B	C-D	E-F
<b>Abstract</b>	Clear and concise with appropriate content, Correct format. 200 words or below	Unclear summary and no specific data, Incorrect form Above 200 words	No specific data with ambiguous information Above 250 words
<b>Introduction</b>	Containing all background details with clear goal and appropriate details, flow specification, no grammar and spelling mistake, well organized sentence and paragraph, reference cited	Unclear and confusing data, appropriate format, grammar and spelling errors with unorganized matter	Out of place depth and content, hazy format
<b>Methods and Procedures</b>	Clear and to the point with well arranged paragraph, precision and accuracy of facts and figures, well organized subheads	Difficult to comprehend with embarrassed text, too much explanation but completed	Incorrect and unorganized structure with hazy meaning
<b>Result</b>	Well organized, Clear and specific, Correct units with precision, correct data, well structuring of paragraph, no grammar and spelling mistake	Complete and embarrassed text, difficult to comprehend	Irregular format with wrong facts and figures
<b>Discussion</b>	Well organized, meaningful specification, sound conclusion, logical and concise explanation, highly structured paragraph reference cited	Wordy, unclear conclusion, spurious	Conclusion is not cited, unorganized, difficult to comprehend
<b>References</b>	Complete and correct format, well organized	Beside the point, Incomplete	Wrong format and structuring







# INDEX

---

---

## A

Adipositasgesellschaft · 16

---

## E

Ethylenediaminetetraacetic · 34

---

## G

Golomb · 12, 17

---

## I

Itraconazole · 32, 35

---

## L

Luxembourg · 26

---

## M

Mycotoxins · 32, 33, 35, 36, 37

---

## X

xylazine · 4

---

## N

Niskayuna · 2, 5

---

## O

Osteosynthesis · 2, 3, 4, 7, 10

---

## R

Randomization · 13

---

## S

Scaffolds · 2, 3, 6

---

## T

Thecontrolgroups · 12  
Trabeculae · 7




save our planet



# Global Journal of Medical Research

Visit us on the Web at [www.GlobalJournals.org](http://www.GlobalJournals.org) | [www.MedicalResearchJournal.org](http://www.MedicalResearchJournal.org)  
or email us at [helpdesk@globaljournals.org](mailto:helpdesk@globaljournals.org)

ISSN 9755896



© Global Journals